<SEC-DOCUMENT>0000049071-24-000021.txt : 20240424
<SEC-HEADER>0000049071-24-000021.hdr.sgml : 20240424
<ACCEPTANCE-DATETIME>20240424063826
ACCESSION NUMBER:		0000049071-24-000021
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20240424
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240424
DATE AS OF CHANGE:		20240424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HUMANA INC
		CENTRAL INDEX KEY:			0000049071
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		ORGANIZATION NAME:           	02 Finance
		IRS NUMBER:				610647538
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-05975
		FILM NUMBER:		24866668

	BUSINESS ADDRESS:	
		STREET 1:		500 W MAIN ST
		CITY:			LOUISVILLE
		STATE:			KY
		ZIP:			40202
		BUSINESS PHONE:		5025801000

	MAIL ADDRESS:	
		STREET 1:		500 W. MAIN ST
		CITY:			LOUISVILLE
		STATE:			KY
		ZIP:			40202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXTENDICARE INC
		DATE OF NAME CHANGE:	19740404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HERITAGE HOUSE OF AMERICA INC
		DATE OF NAME CHANGE:	19671129
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>hum-20240424.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:2b487e96-c580-4c35-9cbd-437df9e49a5a,g:341cf7a6-891e-4b2d-a62f-be78f1573eba,d:0a530c550337433292b15395d10af38e-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>hum-20240424</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0000049071</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="hum-20240424.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-24</xbrli:startDate><xbrli:endDate>2024-04-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0a530c550337433292b15395d10af38e_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC&#160;20549</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.527%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">April 24, 2024</ix:nonNumeric> (April 24, 2024)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.472%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Humana Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.194%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.750%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">1-5975</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">61-0647538</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">500 West Main Street</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Louisville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">KY</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">40202</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">502</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">580-1000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.472%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2. below):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17&#160;CFR&#160;230.425)</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR&#160;240.14d-2(b))</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:36.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.517%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">HUM</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i0a530c550337433292b15395d10af38e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div id="i0a530c550337433292b15395d10af38e_10"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item&#160;7.01&#160;&#160;&#160;&#160;Regulation FD Disclosure.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humana Inc. (the "Company") issued a press release this morning reporting financial results for the quarter ended March 31, 2024, and posted a detailed earnings release related to the same period to the Investor Relations portion of the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.humana.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;A copy of each release is attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and each release is incorporated herein by reference. Additionally, a copy of management's prepared remarks on the Company's financial results for the quarter ended March 31, 2024 and expectations for future earnings, is attached hereto as Exhibit 99.3 and incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i0a530c550337433292b15395d10af38e_13"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits:</span></div><div style="margin-bottom:1pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:6.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:58.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.612%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="hum-2024q18kxex99x1brief.htm">Press Release</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="hum-2024q18kxex99x2detailed.htm">Earnings Release and Statistical Pages</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q2024humanaincpreparedre.htm">Prepared Management Remarks</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="6" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i0a530c550337433292b15395d10af38e_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:1pt;margin-top:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.456%"><tr><td style="width:1.0%"/><td style="width:13.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.651%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMANA INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">/s/ John-Paul W. Felter</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John-Paul W. Felter</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President, Chief Accounting Officer &amp; Controller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Accounting Officer)</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: April 24, 2024</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>hum-2024q18kxex99x1brief.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibdbe61bc8c5449f191e5e800d8d84e72_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div><div style="padding-left:45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:15pt;font-weight:700;line-height:100%">n e w s</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:15pt;font-weight:400;line-height:100%">  r e l e a s e </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 99.1 </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Humana Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">500 West Main Street</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">P.O. Box 1438</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Louisville, KY 40202</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.humana.com</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FOR MORE INFORMATION CONTACT&#58;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lisa Stoner<br>Humana Investor Relations<br>(502) 580-2652<br>e-mail&#58; LStamper&#64;humana.com</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img alt="humanalogoa05.jpg" src="humanalogoa05.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:217px"></div></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mark Taylor</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana Corporate Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(317) 753-0345</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e-mail&#58; MTaylor108&#64;humana.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#5c9a1b;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Humana Reports First Quarter 2024 Financial Results&#59; </font></div><div style="text-align:center"><font style="color:#5c9a1b;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Affirms Full Year Adjusted 2024 Financial Guidance</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Reports 1Q24 earnings per share (EPS) of $6.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a GAAP basis,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EPS of $7.23</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Revises FY 2024 EPS guidance to 'approximately $13.93' (previously 'approximately $14.87') on a GAAP basis, while affirming Adjusted EPS of 'approximately $16.00'&#59; affirms FY 2024 Insurance segment benefit ratio of approximately 90 percent</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Raises 2024 individual Medicare Advantage annual membership growth by 50,000 to now anticipate annual growth of approximately 150,000, or 2.8 percent</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Continues successful track record of organic expansion in Medicaid with recent contract wins in Florida, Texas, and Virginia</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 9&#58;00 a.m. ET question and answer session to discuss its financial results for the quarter and expectations for future earnings</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">LOUISVILLE, KY (April 24, 2024)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> &#8211; Humana Inc. (NYSE&#58; HUM) today reported consolidated pretax results and net  earnings per share (EPS) for the quarter ended March 31, 2024 (1Q24) versus the quarter ended March 31, 2023 (1Q23) as noted in the tables below.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.388%"><tr><td style="width:1.0%"></td><td style="width:68.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated income before income taxes and equity in net earnings (pretax results) </font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">In millions</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q24 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q23 (a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Generally Accepted Accounting Principles (GAAP)</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$1,014</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,614&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with company's non-consolidating  minority interest investments</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction and integration costs</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair market value of publicly-traded equity securities</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$1,191</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,552&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div><div style="padding-left:45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:31.5pt;padding-right:31.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.388%"><tr><td style="width:1.0%"></td><td style="width:68.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net earnings per share (EPS)  </font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q24 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q23 (a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$6.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$9.87&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with company's non-consolidating  minority interest investments</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.42&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction and integration costs</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.41)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair market value of publicly-traded equity securities</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.01</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.64)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.24</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax impact of non-GAAP adjustments</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.34)</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$7.23</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$9.38&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation on disclosures for Adjusted (non-GAAP) </font></div><div style="padding-left:63pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">financial measures, as well as additional reconciliations.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please refer to the tables above, as well as the consolidated and segment highlight sections in the detailed earnings release for additional discussion of the factors impacting the year-over-comparisons.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In addition, a summary of key consolidated and segment statistics comparing 1Q24 to 1Q23 follows.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div><div style="padding-left:45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.416%"><tr><td style="width:1.0%"></td><td style="width:58.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Humana Inc. Summary of Results<br></font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions, except per share amounts)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q23 (a)</font></td></tr><tr><td colspan="9" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">CONSOLIDATED</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues </font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$29,611</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$26,742</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$29,332</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$25,652</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pretax results</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$1,014</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,614</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pretax results - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$1,191</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,552</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EPS</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$6.11</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$9.87</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EPS - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$7.23</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$9.38</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">88.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">85.5&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">88.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">85.9&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cash flows </font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$423</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$6,687</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cash flows - Adjusted (non-GAAP) (b) </font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$423</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$38</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Parent company cash and short term investments</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$509</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$909</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Debt-to-total capitalization</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">45.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.1&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Days in Claims Payable (DCP)</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">42.5</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.2</font></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">INSURANCE SEGMENT</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$28,699</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$25,903</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$28,420</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$24,814</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">89.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">86.1&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">89.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">86.4&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.0&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$898</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,327</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$903</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,252</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">CENTERWELL SEGMENT</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$4,818</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$4,505</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">93.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">91.6&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$282</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$330</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations - Adjusted (non-GAAP) (c)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$335</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$379</font></td></tr></table></div><div style="padding-left:67.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation on disclosures for Adjusted (non-GAAP) </font></div><div style="padding-left:67.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">financial measures, as well as reconciliations.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="ibdbe61bc8c5449f191e5e800d8d84e72_4"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div><div style="padding-left:45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">FY 2024 Earnings Guidance</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana revised its GAAP EPS guidance for the year ending December 31, 2024 (FY 2024) to approximately $13.93 from approximately $14.87, while affirming its Adjusted EPS guidance of approximately $16.00. </font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.416%"><tr><td style="width:1.0%"></td><td style="width:78.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Diluted earnings per common share</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FY 2024<br>&#160;Guidance&#160;(d)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP </font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">approximately $13.93</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.49</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with company's non-consolidating  minority interest investments</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.90</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.24</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative net tax impact of non-GAAP adjustments</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.64)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP) &#8211; FY 2024 projected</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">approximately $16.00</font></td></tr></table></div><div style="padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation on disclosures for Adjusted (non-GAAP) financial measures, as well</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">as additional reconciliations.</font></div><div id="ibdbe61bc8c5449f191e5e800d8d84e72_7"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Detailed Press Release</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana&#8217;s full earnings press release, including the statistical pages, has been posted to the company&#8217;s Investor Relations site and may be accessed at https&#58;&#47;&#47;humana.gcs-web.com&#47; or via a current report on Form 8-K filed by the company with the Securities and Exchange Commission this morning (available at www.sec.gov or on the company&#8217;s website).</font></div><div id="ibdbe61bc8c5449f191e5e800d8d84e72_10"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Conference Call</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Humana will host a live question and answer session for analysts at 9&#58;00 a.m. Eastern time today to discuss its financial results for the quarter and the company&#8217;s expectations for future earnings. In advance of the question and answer session, Humana will post prepared management remarks to the Quarterly Results section of its Investor Relations page (https&#58;&#47;&#47;humana.gcs-web.com&#47;financial-information&#47;quarterly-results).</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">To participate via phone, please register in advance at this link - https&#58;&#47;&#47;register.vevent.com&#47;register&#47;BI6d7513be1a494bbb82b4b8caa62d3b2f. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID that can be used to access the call.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A webcast of the 1Q24 earnings call may also be accessed via Humana&#8217;s Investor Relations page at humana.com.&#160;The company suggests participants for both the conference call and those listening via the web dial in or sign on at least 15 minutes in advance of the call. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For those </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">unable to participate in the live event, the archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page (https&#58;&#47;&#47;humana.gcs-web.com&#47;events-and-presentations), approximately two hours following the live webcast.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div id="ibdbe61bc8c5449f191e5e800d8d84e72_13"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Footnotes</font></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has included financial measures throughout this earnings release that are not in accordance with GAAP. Management believes that these measures, when presented in conjunction with the corresponding GAAP measures, provide a comprehensive perspective to more accurately compare and analyze the company&#8217;s core operating performance over time. Consequently, management uses these non-GAAP (Adjusted) financial measures as consistent and uniform indicators of the company&#8217;s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Non-GAAP (Adjusted) financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. All financial measures in this earnings release are in accordance with </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div><div style="padding-left:45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP unless otherwise indicated. Please refer to the footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) For the periods covered in this earnings press release, the following items are excluded from the non-GAAP financial</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measures described above, as applicable&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Amortization associated with identifiable intangibles -</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Since amortization varies based on the size and timing of acquisition activity, management believes this exclusion provides a more consistent and uniform indicator of performance from period to period. For all periods shown within this earnings release, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP measures affected include consolidated pretax results, EPS, and Insurance and CenterWell segments income from operations. The table below discloses respective period amortization expense for each segment.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.750%"><tr><td style="width:1.0%"></td><td style="width:36.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance segment</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$4</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell segment</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$12</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Put&#47;call valuation adjustments </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">associated with company&#8217;s non-consolidating minority interest investments - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts are the result of fair value measurements associated with the company's Primary Care Organization strategic partnership and are unrelated to the company's core business operations. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results and EPS</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Transaction and integration costs -</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The transaction and integration costs primarily relate to the acquisition of Kindred at Home in 2021 and the subsequent divestiture of Gentiva (formerly Kindred) Hospice in 2022.  For 1Q23, GAAP measures affected include consolidated pretax results, EPS, and the consolidated operating cost ratio.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Change in fair market value of publicly-traded equity securities - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These gains and losses are a result of market and economic conditions that are unrelated to the company's core business operations.  For 1Q23, GAAP measures affected include consolidated pretax results, EPS, and consolidated revenues (specifically investment income).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.02pt">I</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">mpact of exit of employer group commercial medical products business - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period segment financial information has been recast to exclude the impact of the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023.  For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results, EPS, consolidated revenues, consolidated benefit ratio, consolidated operating cost ratio, Insurance segment revenues, Insurance segment benefit ratio, Insurance segment operating cost ratio, and Insurance segment income from operations.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Value creation initiatives - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These charges relate to the company's ongoing initiative to drive additional value for the enterprise through cost saving, productivity initiatives, and value creation from previous investments, and primarily consist of asset impairment and severance charges. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 1Q24, GAAP measures affected in this release include consolidated pretax results, EPS, and the consolidated operating cost ratio.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Cumulative net tax impact of non-GAAP adjustments - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment represents the cumulative net impact of the corresponding tax benefit or expense related to the aforementioned items excluded from the applicable GAAP measures.  For all periods presented in this earnings release, EPS is the sole GAAP measure affected.  </font></div><div style="margin-top:3pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the reconciliations shown on</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pages 1 and 2</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release&#58;</font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Revenues</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.361%"><tr><td style="width:1.0%"></td><td style="width:60.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues - CONSOLIDATED<br>(in millions)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$29,611</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$26,742</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of publicly-traded equity securities</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(279)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$29,332</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$25,652</font></td></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div><div style="padding-left:45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.500%"><tr><td style="width:1.0%"></td><td style="width:60.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues - INSURANCE SEGMENT<br>(in millions)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$28,699</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$25,903</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(279)</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$28,420</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$24,814</font></td></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Benefit Ratio </font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.694%"><tr><td style="width:1.0%"></td><td style="width:61.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.565%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit ratio - CONSOLIDATED</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.9&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.694%"><tr><td style="width:1.0%"></td><td style="width:61.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.565%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit ratio - INSURANCE SEGMENT</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.1&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="padding-left:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Operating Cost Ratio </font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.694%"><tr><td style="width:1.0%"></td><td style="width:61.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating cost ratio - CONSOLIDATED</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.694%"><tr><td style="width:1.0%"></td><td style="width:61.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating cost ratio - INSURANCE SEGMENT</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Income from Operations</font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.694%"><tr><td style="width:1.0%"></td><td style="width:61.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.565%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from operations - INSURANCE SEGMENT</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$898</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,327</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$4</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$903</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,252</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Generally, when the first day of a month falls on a weekend or holiday, with the exception of January 1 (New Year's Day), the</font></div><div style="padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company receives its monthly Medicare premium payment from CMS on the last business day of the previous month. On a GAAP</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div><div style="padding-left:45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis, this can result in certain quarterly cash flows from operations including more or less than three monthly payments. Consequently, when this occurs, the company reports Adjusted cash flows from operations to reflect three payments in each quarter to match the related expenses.</font></div><div><font><br></font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.916%"><tr><td style="width:1.0%"></td><td style="width:60.579%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash from operating activities</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$423</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,687</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timing of premium payment from CMS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,649)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP) </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$423</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$38</font></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)  The CenterWell segment Adjusted income from operations includes an adjustment to add back depreciation and amortization expense to the segment's GAAP income from operations since such an adjustment is commonly utilized for valuation purposes within the healthcare delivery industry. </font></div><div style="margin-top:12pt;padding-left:28.12pt;padding-right:28.12pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.694%"><tr><td style="width:1.0%"></td><td style="width:63.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.521%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income from operations - CENTERWELL SEGMENT<br>(in millions)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$282</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$330</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$335</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$379&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) FY 2024 projected Adjusted results exclude the future impact of items that cannot be estimated at this time. </font></div><div style="padding-left:18pt;text-align:justify;text-indent:4.5pt"><font><br></font></div><div id="ibdbe61bc8c5449f191e5e800d8d84e72_16"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Cautionary Statement</font></div><div style="margin-top:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana&#8217;s executive officers, the words or phrases like &#8220;expects,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;likely will result,&#8221; &#8220;estimates,&#8221; &#8220;projects&#8221; or variations of such words and similar expressions are intended to identify such forward-looking statements.  </font></div><div><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the &#8220;Risk Factors&#8221; section of the company&#8217;s SEC filings, a summary of which includes but is not limited to the following&#58;  </font></div><div style="margin-bottom:2.4pt;padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana&#8217;s profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit expenses for services incurred in the current and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves, where appropriate. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana's reserves may be insufficient.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, which are of particular importance given the concentration of the company's revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div><div style="padding-left:45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">care delivery model, the company&#8217;s business may be materially adversely affected. In addition, there can be no assurances that the company will be successful in maintaining or improving its Star ratings in future years.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana, or the third-party service providers on which it relies, fails to properly maintain the integrity of its data, to strategically maintain existing or implement new information systems, to protect Humana&#8217;s proprietary rights to its systems, or to defend against cyber-security attacks, contain such attacks when they occur, or prevent other privacy or data security incidents that result in security breaches that disrupt the company's operations or in the unintentional dissemination of sensitive personal information or proprietary or confidential information, the company&#8217;s business may be materially adversely affected.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company&#8217;s cost of doing business.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government healthcare programs including, among other things, loss of material government contracts&#59; governmental audits and investigations&#59; potential inadequacy of government determined payment rates&#59; potential restrictions on profitability, including by comparison of profitability of the company&#8217;s Medicare Advantage business to non-Medicare Advantage business&#59; or other changes in the governmental programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the risk adjustment data validation audit methodology published by CMS on January 30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act due to its failure to include a &#34;Fee for Service Adjuster&#34; could have a material adverse effect on the company's operating results, financial position and cash flows. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana's business activities are subject to substantial government regulation.  New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase the company's cost of doing business and have a material adverse effect on Humana&#8217;s results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company&#8217;s ability to expand into new markets, increasing the company&#8217;s medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering the company&#8217;s Medicare payment rates and increasing the company&#8217;s expenses associated with a non-deductible health insurance industry fee and other assessments)&#59; the company&#8217;s financial position (including the company&#8217;s ability to maintain the value of its goodwill)&#59; and the company&#8217;s cash flows.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company&#8217;s results of operations, financial position, and cash flows. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company&#8217;s business may be adversely affected.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">Humana faces significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to the Company&#8217;s success, and its failure to do so could adversely affect the Company&#8217;s businesses, operating results and&#47;or future performance.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s pharmacy business is highly competitive and subjects it to regulations and supply chain risks in addition to those the company faces with its core health benefits businesses.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Changes in the prescription drug industry pricing benchmarks may adversely affect Humana&#8217;s financial performance.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.  </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div><div style="padding-left:45pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Downgrades in Humana&#8217;s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio.    </font></div><div style="padding-left:36pt;text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Form 10-K for the year ended December&#160;31, 2023&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Form 8-Ks filed during 2024. </font></div><div><font><br></font></div><div><font><br></font></div><div id="ibdbe61bc8c5449f191e5e800d8d84e72_19"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">About Humana </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana Inc. is committed to putting health first &#8211; for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health &#8211; delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.  </font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>hum-2024q18kxex99x2detailed.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie9f95947fa4b47bb9d4fac3545599c9f_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:14.027%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">n e w s  r e l e a s e</font></td><td colspan="3" style="display:none"></td></tr></table><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.555%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 99.2</font></td></tr></table></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:125.25pt"><tr><td style="width:1.0pt"></td><td style="width:123.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:60pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">500 West Main Street</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">P.O. Box 1438</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Louisville, KY 40202</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.humana.com</font></div></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FOR MORE INFORMATION CONTACT&#58;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lisa Stoner<br>Humana Investor Relations<br>(502) 580-2652<br>e-mail&#58; LStamper&#64;humana.com</font></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><img alt="humanalogoa051.jpg" src="humanalogoa051.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:217px"></div></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mark Taylor</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana Corporate Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(317) 753-0345</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e-mail&#58; MTaylor108&#64;humana.com</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#5c9a1b;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Humana Reports First Quarter 2024 Financial Results&#59; </font></div><div style="text-align:center"><font style="color:#5c9a1b;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Affirms Full Year Adjusted 2024 Financial Guidance </font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Reports 1Q24 earnings per share (EPS) of $6.11 on a GAAP basis, Adjusted EPS of $7.23</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Revises FY 2024 EPS guidance to 'approximately $13.93' (previously 'approximately $14.87') on a GAAP basis, while affirming Adjusted EPS of 'approximately $16.00'&#59; affirms FY 2024 Insurance segment benefit ratio of approximately 90 percent </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Raises 2024 individual Medicare Advantage annual membership growth by 50,000 to now anticipate annual growth of approximately 150,000, or 2.8 percent</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Continues successful track record of organic expansion in Medicaid with recent contract wins in Florida, Texas, and Virginia </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 9&#58;00 a.m. ET question and answer session to discuss its financial results for the quarter and expectations for future earnings</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">LOUISVILLE, KY (April 24, 2024)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> &#8211; Humana Inc. (NYSE&#58; HUM) today reported consolidated pretax results and net  earnings per share (EPS) for the quarter ended March 31, 2024 (1Q24) versus the quarter ended March 31, 2023 (1Q23) as noted in the tables below.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.388%"><tr><td style="width:1.0%"></td><td style="width:68.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated income before income taxes and equity in net earnings (pretax results) </font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">In millions</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q24 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q23 (a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Generally Accepted Accounting Principles (GAAP)</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$1,014</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,614&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with company's non-consolidating  minority interest investments</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">131</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction and integration costs</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair market value of publicly-traded equity securities</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$1,191</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,552&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:31.5pt;padding-right:31.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.388%"><tr><td style="width:1.0%"></td><td style="width:68.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net earnings per share (EPS)  </font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q24 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1Q23 (a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$6.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$9.87&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with company's non-consolidating  minority interest investments</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.42&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction and integration costs</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.41)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair market value of publicly-traded equity securities</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.01</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.64)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.24</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax impact of non-GAAP adjustments</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.34)</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$7.23</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$9.38&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:63pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation on disclosures for Adjusted (non-GAAP) </font></div><div style="padding-left:63pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">financial measures, as well as additional reconciliations.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Please refer to the tables above, as well as the consolidated and segment highlight sections that follow for additional discussion of the factors impacting the year-over-year comparisons. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In addition, a summary of key consolidated and segment statistics comparing 1Q24 to 1Q23 follows.</font></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_7"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.416%"><tr><td style="width:1.0%"></td><td style="width:58.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Humana Inc. Summary of Results<br></font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions, except per share amounts)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q23 (a)</font></td></tr><tr><td colspan="9" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">CONSOLIDATED</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues </font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$29,611</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$26,742</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$29,332</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$25,652</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pretax results</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$1,014</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,614</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pretax results - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$1,191</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,552</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EPS</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$6.11</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$9.87</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EPS - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$7.23</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$9.38</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">88.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">85.5&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">88.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">85.9&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cash flows </font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$423</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$6,687</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cash flows - Adjusted (non-GAAP) (b) </font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$423</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$38</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Parent company cash and short term investments</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$509</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$909</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Debt-to-total capitalization</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">45.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.1&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Days in Claims Payable (DCP)</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">42.5</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.2</font></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">INSURANCE SEGMENT</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$28,699</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$25,903</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$28,420</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$24,814</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">89.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">86.1&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">89.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">86.4&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.0&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$898</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,327</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$903</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,252</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">CENTERWELL SEGMENT</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$4,818</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$4,505</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">93.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">91.6&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$282</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$330</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations - Adjusted (non-GAAP) (c)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$335</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$379</font></td></tr></table></div><div style="padding-left:15.75pt;padding-right:15.75pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation on disclosures for Adjusted (non-GAAP) </font></div><div style="padding-left:67.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">financial measures, as well as reconciliations.</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_13"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">FY 2024 Earnings Guidance</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana revised its GAAP EPS guidance for the year ending December 31, 2024 (FY 2024) to approximately $13.93 from approximately $14.87, while affirming its Adjusted EPS guidance of approximately $16.00. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additional FY 2024 guidance points are included on page 15 of this earnings release.</font></div><div style="padding-right:-11.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.416%"><tr><td style="width:1.0%"></td><td style="width:78.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Diluted earnings per common share</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FY 2024<br>&#160;Guidance&#160;(d)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP </font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">approximately $13.93</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of identifiable intangibles</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.49</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Put&#47;call valuation adjustments associated with company's non-consolidating  minority interest investments</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.08</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.90</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.24</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative net tax impact of non-GAAP adjustments</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.64)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP) &#8211; FY 2024 projected</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">approximately $16.00</font></td></tr></table></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">Refer to the &#34;Footnotes&#34; section included herein for further explanation on disclosures for Adjusted (non-GAAP) financial measures, as well</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">as additional reconciliations.</font></div><div><font><br></font></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_19"></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Humana Consolidated Highlights</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.416%"><tr><td style="width:1.0%"></td><td style="width:58.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Humana Inc. Summary of Results<br></font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions, except per share amounts)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q23 (a)</font></td></tr><tr><td colspan="9" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">CONSOLIDATED</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues </font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$29,611</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$26,742</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$29,332</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$25,652</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pretax results</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$1,014</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,614</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pretax results - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$1,191</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,552</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EPS</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$6.11</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$9.87</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EPS - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$7.23</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$9.38</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">88.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">85.5&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">88.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">85.9&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cash flows </font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$423</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$6,687</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cash flows - Adjusted (non-GAAP) (b) </font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$423</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$38</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Parent company cash and short term investments</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$509</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$909</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Debt-to-total capitalization</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">45.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.1&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Days in Claims Payable (DCP)</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">42.5</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.2</font></td></tr></table></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Refer to the &#34;Footnotes&#34; section included herein for further explanation on disclosures for Adjusted (non-GAAP) </font></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">financial measures, as well as reconciliations.</font></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_25"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Consolidated Revenues</font></div><div style="margin-top:7pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">favorable</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> year-over-year consolidated revenues comparison was primarily driven by the following factors&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">higher per member</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Medicare premiums and </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">individual and group Medicare Advantage membership growth.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These factors were partially offset by the continued decline in the company's group commercial medical and stand-alone PDP membership, as well as a decline in state-based contracts membership as a result of the end of the suspension of state eligibility redetermination efforts previously enacted as part of the Public Health Emergency.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) consolidated revenues for the respective periods. </font></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_31"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Consolidated Benefit Ratio</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The year-over-year </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">increase </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">in the GAAP consolidated ratio primarily reflected higher Medicare Advantage medical cost trends in 1Q24 compared to 1Q23.  This was partially offset by t</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">he impact of pricing and benefit design of the company's 2024 Medicare Advantage products, which included a reduction in benefits in response to the net impact of the final rate notice and the initial emergence of increased medical cost trends. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Furthermore, the year-over-year comparison continues to reflect a shift in line of business mix, with growth in Medicare Advantage and state-based contracts and other membership, which can carry a higher benefit ratio.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) consolidated benefit ratio for the respective periods. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Prior Period Medical Claims Reserve Development (Prior Period Development)</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.472%"><tr><td style="width:1.0%"></td><td style="width:37.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#5c9a1b;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Consolidated Favorable Prior Period Development</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">$ in millions</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Basis points (bps)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First<br>Quarter</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prior Period Development from prior years recognized in 2024 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$535</font></td></tr><tr><td colspan="9" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Decrease to GAAP benefit ratio</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(190 bps)</font></td></tr><tr><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prior Period Development from prior years recognized in 2023 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$522</font></td></tr><tr><td colspan="9" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Decrease to GAAP benefit ratio</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(200 bps)</font></td></tr></table></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_37"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Consolidated Operating Cost Ratio</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The year-over-year decrease in the GAAP consolidated operating cost ratio from the 2023 quarter primarily related to the following&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">scale efficiencies associated with growth in the company's individual Medicare Advantage membership, </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">administrative cost efficiencies resulting from the company's value creation initiatives, and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">lower commission expense for brokers in 1Q24 compared to 1Q23 as a result of the significant individual Medicare Advantage membership growth in 2023.</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These factors were partially offset by </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the impact from charges related to value creation initiatives in 1Q24.  These charges were recorded at the corporate level and not allocated to the segments.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) consolidated operating cost ratio for the respective periods. </font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_43"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Balance sheet</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Days in claims payable (DCP) of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">42.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> days at March 31, 2024 represented an i</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ncrease</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of 1.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">days from 41.4 days at December 31, 2023, and an in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">crease</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of 1.3</font><font style="background-color:#ffffff;color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">days from 41.2 days at March 31, 2023. </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 1.1</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">day sequential increase was primarily driven by</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a higher incurred but not reported (IBNR) balance as a result of the Change Healthcare disruption in February 2024, partially offset by seasonality related to net pharmacy expenses.  </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The 1.3 day y</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">ear-over-year increase </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">was primarily driven by</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">a higher incurred but not reported (IBNR) balance as a result of the Change Healthcare disruption in February 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">, partially offset by lower reserve requirements in provider-capitation accruals due to lower performance-based payment expectations. </font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">Humana's debt-to-total capitalization at March 31</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">, 2024 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">increased 330 basis points to 45.1 percent fro</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">m 41.8 p</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">ercent at </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">December 31, 2023 primarily driven by t</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">he previously disclosed $2.25 billion issuance of senior notes in March 2024 and </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">a decrease in total capitalization as a result of 1Q24 open market share repurchases, p</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">artially offset by 1Q24 net earnings and repayment of commercial paper balances.</font></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_49"></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Operating cash flows</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The year-over-year decline in GAAP operating cash flows primarily reflected the significant impact of the early receipt of the $6.65 billion April 2023 premium payment from CMS in March 2023</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline">(b) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">and lower earnings in 1Q24.   </font></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_55"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Share repurchases</font></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.083%"><tr><td style="width:1.0%"></td><td style="width:68.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total number of shares repurchased</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1,804,645</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Average price paid per share</font></td><td style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">388.78</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Remaining repurchase authorization as of April 23, 2024 </font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$2.96 billion</font></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective February 16, 2024, the Board of Directors replaced the previous share authorization of up to $3 billion (of which approximately $824 million remained unused) with a new authorization for repurchases of up to $3 billion of Humana Inc. common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027.</font></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_64"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Humana&#8217;s Insurance Segment</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This segment is comprised of insurance products serving Medicare and state-based contract beneficiaries, as well as individuals and employers. The segment also includes the company's Pharmacy Benefit Manager, or PBM, business.   </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.194%"><tr><td style="width:1.0%"></td><td style="width:55.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insurance Segment Results</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">$ in millions</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24 (a)</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q23 (a)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$28,699</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$25,903</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$28,420</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$24,814</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">89.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">86.1&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefit ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">89.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">86.4&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio - Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.0&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$898</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,327</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations - Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$903</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,252</font></td></tr></table></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation on disclosures for Adjusted </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(non-GAAP) financial measures, as well as reconciliations.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Insurance Segment Revenues</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The year-over-year </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increase</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in GAAP segment revenues from the 2023 quarter primarily reflects the following items&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">higher per member</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Medicare premiums and </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">individual and group Medicare Advantage membership growth.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These factors were partially offset by the continued decline in the company's group commercial medical and stand-alone PDP membership, as well as a decline in state-based contracts membership as a result of the end of the suspension of state eligibility redetermination efforts previously enacted as part of the Public Health Emergency.  </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) Insurance segment revenues for the respective periods. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Insurance Segment Benefit Ratio</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The year-over-year </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">increase </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">in the GAAP segment ratio primarily reflected higher Medicare Advantage medical cost trends in 1Q24 compared to 1Q23. This was partially offset by </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the impact of pricing and benefit design of the company's 2024 Medicare Advantage products, which included a reduction in benefits in response to the net impact of the final rate notice and the initial emergence of increased medical cost trends.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Furthermore, the year-over-year comparison continues to reflect a shift in line of business mix, with growth in Medicare Advantage and state-based contracts and other membership, which can carry a higher benefit ratio.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) Insurance segment benefit ratio for the respective periods. </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Insurance Segment Operating Cost Ratio</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The year-over-year decrease in the GAAP segment operating cost ratio from the 2023 quarter primarily related to the following&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">scale efficiencies associated with growth in the company's individual Medicare Advantage membership, </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">administrative cost efficiencies resulting from the company's value creation initiatives, and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">lower commission expense for brokers in 1Q24 compared to 1Q23 as a result of the significant individual Medicare Advantage membership growth in 2023.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) Insurance segment operating cost ratio for the respective periods. </font></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_76"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Humana&#8217;s CenterWell Segment</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This segment includes pharmacy (excluding the PBM operations), primary care, and home solutions.  The segment also includes the impact of non-consolidating minority interest investments related to the company's strategic partnerships with Welsh, Carson, Anderson &#38; Stowe (WCAS) to develop and operate senior-focused, payor-agnostic, primary care centers, as well as the Gentiva (formerly Kindred) Hospice</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">operations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and&#47;or lower drug costs.</font></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.055%"><tr><td style="width:1.0%"></td><td style="width:51.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.370%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CenterWell Segment Results</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">$ in millions</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q24 </font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1Q23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$4,818</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$4,505</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">93.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">91.6&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$282</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$330</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations - Adjusted (non-GAAP) (c)</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$335</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$379</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:85.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Refer to the &#34;Footnotes&#34; section included herein for further explanation on disclosures for Adjusted</font></div><div style="padding-left:85.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(non-GAAP) financial measures, as well as reconciliation.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CenterWell Segment Revenues</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CenterWell segment revenues </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increased</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in 1Q24 compared to 1Q23, which was impacted by the following </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">factors&#58;</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">greater intersegment revenues associated with the Home Solutions business in 1Q24 as compared to 1Q23 as a result of the expansion of the value-based home care model and</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">higher revenues associated with growth in the company's Primary Care business, partially offset by the impact of the v28 risk model revision.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">CenterWell Segment Operating Cost Ratio</font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The year-over-year</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> increase i</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">n the segment's operating cost ratio compared to the 2023 quarter primarily resulted from the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">unfavorable impact of the v28 risk model revision to the company's Primary Care business.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">See additional operational metrics for the CenterWell segment on pages S-10 through S-12 of the statistical supplement included in this earnings release.</font></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_82"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Conference Call</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Humana will host a live question and answer session for analysts at 9&#58;00 a.m. Eastern time today to discuss its financial results for the quarter and the company&#8217;s expectations for future earnings. In advance of the question and answer </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">session, Humana will post prepared management remarks to the Quarterly Results section of its Investor Relations page (https&#58;&#47;&#47;humana.gcs-web.com&#47;financial-information&#47;quarterly-results).</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">To participate via phone, please register in advance at this link - https&#58;&#47;&#47;register.vevent.com&#47;register&#47;BI6d7513be1a494bbb82b4b8caa62d3b2f. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID that can be used to access the call.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A webcast of the 1Q24 earnings call may also be accessed via Humana&#8217;s Investor Relations page at humana.com.&#160;The company suggests participants for both the conference call and those listening via the web dial in or sign on at least 15 minutes in advance of the call. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For those </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">unable to participate in the live event, the archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page (https&#58;&#47;&#47;humana.gcs-web.com&#47;events-and-presentations), approximately two hours following the live webcast.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_85"></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Footnotes</font></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has included financial measures throughout this earnings release that are not in accordance with GAAP. Management believes that these measures, when presented in conjunction with the corresponding GAAP measures, provide a comprehensive perspective to more accurately compare and analyze the company&#8217;s core operating performance over time. Consequently, management uses these non-GAAP (Adjusted) financial measures as consistent and uniform indicators of the company&#8217;s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Non-GAAP (Adjusted) financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. All financial measures in this earnings release are in accordance with GAAP unless otherwise indicated. Please refer to the footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) For the periods covered in this earnings press release, the following items are excluded from the non-GAAP financial</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measures described above, as applicable&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Amortization associated with identifiable intangibles -</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Since amortization varies based on the size and timing of acquisition activity, management believes this exclusion provides a more consistent and uniform indicator of performance from period to period. For all periods shown within this earnings release, </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP measures affected include consolidated pretax results, EPS, and Insurance and CenterWell segments income from operations. The table below discloses respective period amortization expense for each segment.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.750%"><tr><td style="width:1.0%"></td><td style="width:36.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance segment</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$4</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell segment</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$12</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12</font></td></tr></table></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Put&#47;call valuation adjustments </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">associated with company&#8217;s non-consolidating minority interest investments - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts are the result of fair value measurements associated with the company's Primary Care Organization strategic partnership and are unrelated to the company's core business operations. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results and EPS</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Transaction and integration costs -</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The transaction and integration costs primarily relate to the acquisition of Kindred at Home in 2021 and the subsequent divestiture of Gentiva (formerly Kindred) Hospice in 2022.  For 1Q23, GAAP measures affected include consolidated pretax results, EPS, and the consolidated operating cost ratio.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Change in fair market value of publicly-traded equity securities - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These gains and losses are a result of market and economic conditions that are unrelated to the company's core business operations.  For 1Q23, GAAP measures affected include consolidated pretax results, EPS, and consolidated revenues (specifically investment income).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.02pt">I</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">mpact of exit of employer group commercial medical products business - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period segment financial information has been recast to exclude the impact of the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023.  For all periods shown within this earnings release, GAAP measures affected include </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated pretax results, EPS, consolidated revenues, consolidated benefit ratio, consolidated operating cost ratio, Insurance segment revenues, Insurance segment benefit ratio, Insurance segment operating cost ratio, and Insurance segment income from operations.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Value creation initiatives - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These charges relate to the company's ongoing initiative to drive additional value for the enterprise through cost saving, productivity initiatives, and value creation from previous investments, and primarily consist of asset impairment and severance charges. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 1Q24, GAAP measures affected in this release include consolidated pretax results, EPS, and the consolidated operating cost ratio.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Cumulative net tax impact of non-GAAP adjustments - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment represents the cumulative net impact of the corresponding tax benefit or expense related to the aforementioned items excluded from the applicable GAAP measures.  For all periods presented in this earnings release, EPS is the sole GAAP measure affected.  </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the reconciliations shown on</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pages 1 and 2</font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Revenues</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.361%"><tr><td style="width:1.0%"></td><td style="width:60.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues - CONSOLIDATED</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$29,611</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$26,742</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of publicly-traded equity securities</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(279)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$29,332</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$25,652</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.500%"><tr><td style="width:1.0%"></td><td style="width:60.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues - INSURANCE SEGMENT</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$28,699</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$25,903</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(279)</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$28,420</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$24,814</font></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Benefit Ratio </font></div><div style="padding-left:18pt;text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.694%"><tr><td style="width:1.0%"></td><td style="width:61.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.565%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit ratio - CONSOLIDATED</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.9&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.694%"><tr><td style="width:1.0%"></td><td style="width:61.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.565%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit ratio - INSURANCE SEGMENT</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.1&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:22.5pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Operating Cost Ratio </font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.694%"><tr><td style="width:1.0%"></td><td style="width:61.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.565%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating cost ratio - CONSOLIDATED</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value creation initiatives</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="background-color:#def3c0;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.694%"><tr><td style="width:1.0%"></td><td style="width:61.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.565%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating cost ratio - INSURANCE SEGMENT</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.1)</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:115%;text-decoration:underline">Income from Operations</font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.694%"><tr><td style="width:1.0%"></td><td style="width:61.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.565%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from operations - INSURANCE SEGMENT</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$898</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,327</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization associated with identifiable intangibles</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</font></td><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of exit of employer group commercial medical products business</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</font></td><td style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$903</font></td><td colspan="3" style="background-color:#def3c0;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,252</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:4.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Generally, when the first day of a month falls on a weekend or holiday, with the exception of January 1 (New Year's Day), the</font></div><div style="padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company receives its monthly Medicare premium payment from CMS on the last business day of the previous month. On a GAAP</font></div><div style="padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis, this can result in certain quarterly cash flows from operations including more or less than three monthly payments. Consequently, when this occurs, the company reports Adjusted cash flows from operations to reflect three payments in each quarter to match the related expenses.</font></div><div style="padding-left:4.5pt;text-align:justify"><font><br></font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.916%"><tr><td style="width:1.0%"></td><td style="width:60.579%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash from operating activities</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$423</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,687</font></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timing of premium payment from CMS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,649)</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$423</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$38</font></td></tr></table></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)  The CenterWell segment Adjusted income from operations includes an adjustment to add back depreciation and amortization expense to the segment's GAAP income from operations since such an adjustment is commonly utilized for valuation purposes within the healthcare delivery industry. </font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.138%"><tr><td style="width:1.0%"></td><td style="width:58.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.157%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from operations - CENTERWELL SEGMENT</font></div><div><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></div></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q24</font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1Q23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$282</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$330</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</font></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#def3c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#def3c0;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="background-color:#def3c0;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted (non-GAAP)</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$335</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$379&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:4.5pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) FY 2024 projected Adjusted results exclude the future impact of items that cannot be estimated at this time. </font></div><div style="padding-left:18pt;text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(e) Prior Period Development related to the employer group commercial medical products business&#58;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.750%"><tr><td style="width:1.0%"></td><td style="width:85.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.139%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Favorable </font></td><td colspan="3" style="background-color:#5c9a1b;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First Quarter</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior Period Development from prior years recognized in 2024 </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$34</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior Period Development from prior years recognized in 2023</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_97"></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Cautionary Statement</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana&#8217;s executive officers, the words or phrases like &#8220;expects,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;likely will result,&#8221; &#8220;estimates,&#8221; &#8220;projects&#8221; or variations of such words and similar expressions are intended to identify such forward-looking statements.  </font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the &#8220;Risk Factors&#8221; section of the company&#8217;s SEC filings, a summary of which includes but is not limited to the following&#58;  </font></div><div style="margin-bottom:2.4pt;padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana&#8217;s profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit expenses for services incurred in the current and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves, where appropriate. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana's reserves may be insufficient.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, which are of particular importance given the concentration of the company's revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated care delivery model, the company&#8217;s business may be materially adversely affected. In addition, there can be no assurances that the company will be successful in maintaining or improving its Star ratings in future years.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana, or the third-party service providers on which it relies, fails to properly maintain the integrity of its data, to strategically maintain existing or implement new information systems, to protect Humana&#8217;s proprietary rights to its systems, or to defend against cyber-security attacks, contain such attacks when they occur, or prevent other privacy or data security incidents that result in security breaches that disrupt the company's operations or in the unintentional dissemination of sensitive personal information or proprietary or confidential information, the company&#8217;s business may be materially adversely affected.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company&#8217;s cost of doing business.  </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government healthcare programs including, among other things, loss of material government contracts&#59; governmental audits and investigations&#59; potential inadequacy of government determined payment rates&#59; potential restrictions on profitability, including by comparison of profitability of the company&#8217;s Medicare Advantage business to non-Medicare Advantage business&#59; or other changes in the governmental programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the risk adjustment data validation audit methodology published by CMS on January 30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act due to its failure to include a &#34;Fee for Service Adjuster&#34; could have a material adverse effect on the company's operating results, financial position and cash flows. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana's business activities are subject to substantial government regulation.  New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase the company's cost of doing business and have a material adverse effect on Humana&#8217;s results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company&#8217;s ability to expand into new markets, increasing the company&#8217;s medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering the company&#8217;s Medicare payment rates and increasing the company&#8217;s expenses associated with a non-deductible health insurance industry fee and other assessments)&#59; the company&#8217;s financial position (including the company&#8217;s ability to maintain the value of its goodwill)&#59; and the company&#8217;s cash flows.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company&#8217;s results of operations, financial position, and cash flows. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company&#8217;s business may be adversely affected.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">Humana faces significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to the Company&#8217;s success, and its failure to do so could adversely affect the Company&#8217;s businesses, operating results and&#47;or future performance.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s pharmacy business is highly competitive and subjects it to regulations and supply chain risks in addition to those the company faces with its core health benefits businesses.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Changes in the prescription drug industry pricing benchmarks may adversely affect Humana&#8217;s financial performance.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Humana&#8217;s ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Downgrades in Humana&#8217;s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio.    </font></div><div style="padding-left:36pt;text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.  </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Form 10-K for the year ended December&#160;31, 2023&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Form 8-Ks filed during 2024. </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_100"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">About Humana </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humana Inc. is committed to putting health first &#8211; for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health &#8211; delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.  </font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:23.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%;text-decoration:underline">Humana Inc. Full Year 2024 Projections - As of April 24, 2024</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">n accordance with GAAP unless otherwise noted</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Current Guidance</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Prior Guidance</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Diluted earnings per common share</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">approximately $13.93</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">approximately $14.87</font></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> approximately $16.00</font></div></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Total Revenues</font></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> approximately $113 billion</font></div></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consolidated and segment level revenue projections include expected investment income.<br>Segment level revenues include amounts that eliminate in consolidation.</font></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance segment</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">approximately</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110 billion</font></div></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell segment</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> approximately $19 billion </font></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Change in year-end medical membership from prior year-end</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Growth of approximately 150,000</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Growth of approximately 100,000</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Growth of approximately 45,000</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decline of approximately 650,000</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Growth of approximately 250,000</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">State-based contracts guidance includes membership in Florida, Illinois,  Indiana, Kentucky, Louisiana, Ohio, Oklahoma, South Carolina, and Wisconsin.</font></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Ratio</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Insurance segment</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> approximately 90.0%</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ratio calculation&#58; benefits expense as a percent of premiums revenues.</font></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Cost Ratio </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">            Consolidated</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">approximately</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4%</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ratio calculation&#58; operating costs excluding depreciation and amortization as a percent of revenues excluding investment income.</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Segment Results</font></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance segment income from operations</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">approximately $1.2 billion</font></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell segment income from operations</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> approximately $1.4 billion</font></div></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Tax Rate</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> approximately 25.2%</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">approximately 25.0%</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> approximately 24.5%</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Avg. Share Count for Diluted EPS</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">approximately 121 million</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">approximately 122 million</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operations</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> approximately $2 billion</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Capital expenditures</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">no change</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> approximately $800 million</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_106"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:40pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:40pt;font-weight:400;line-height:120%">Statistical Schedules</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:40pt;font-weight:400;line-height:120%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:40pt;font-weight:400;line-height:120%">Supplementary Information</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:40pt;font-weight:400;line-height:120%">1Q24 Earnings Release</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-1</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_109"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:center;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.833%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Humana Inc.<br>Statistical Schedules and Supplementary Information <br>1Q24 Earnings Release </font></td></tr><tr style="height:5pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-3) </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated Statements of Income</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-5)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows </font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-6) - (S-7)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidating Statements of Income - Quarter</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-8)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Membership Detail</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-9) </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Premiums and Services Revenue Detail</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-10) - (S-12)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CenterWell Segment - Pharmacy Solutions, Primary Care, &#38; Home Solutions</font></td></tr><tr><td colspan="3" style="padding:2px 19pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(S-13)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Footnotes</font></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-2</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_115"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Consolidated Statements of Income (Unaudited)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Dollars in millions, except per common share results</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.312%"><tr><td style="width:1.0%"></td><td style="width:61.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">For&#160;the&#160;three&#160;months&#160;ended&#160;March 31,</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Premiums</font></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">28,261</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,550&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Services</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1,062</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">999&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Investment income</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">288</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">193&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total revenues</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">29,611</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26,742&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benefits</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">25,124</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,858&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating costs</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3,042</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,979&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">209</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">28,375</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25,023&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Income from operations</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1,236</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,719&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">159</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">113&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other expense (income), net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">63</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Income before income taxes and equity in net earnings</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1,014</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,614&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision from income taxes</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">251</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">359&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity in net losses (A)</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(24)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net income</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">739</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,238&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net income attributable to Humana</font></td><td style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">741</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,239&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic earnings per common share</font></td><td style="border-left:1pt solid #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-left:1pt solid #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.91&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Diluted earnings per common share</font></td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.87&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Shares used in computing basic earnings per common share (000&#8217;s)</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">120,978</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">125,005&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Shares used in computing diluted earnings per common share (000&#8217;s)</font></td><td colspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">121,268</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">125,564&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:1pt"><font><br></font></div><div style="margin-bottom:1pt"><font><br></font></div><div style="margin-bottom:1pt"><font><br></font></div><div style="margin-bottom:1pt"><font><br></font></div><div style="margin-bottom:1pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-3</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_121"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets (Unaudited)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Dollars in millions, except share amounts</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.062%"><tr><td style="width:1.0%"></td><td style="width:72.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.023%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December&#160;31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,910</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,694&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment securities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,697</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,626&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivables, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,925</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,035&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,264</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,631&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32,796</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,986&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,979</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,030&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term investment securities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">380</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">730</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">740&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,563</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,550&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,643</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,377&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,091</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,065&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities and Stockholders&#8217; Equity</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits payable</font></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,729</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,241&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade accounts payable and accrued expenses</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,504</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,569&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Book overdraft</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">333</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unearned revenues</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">301</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">822</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,689</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,872&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,390</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,213&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,826</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,662&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33,905</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,747&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $1 par&#59; 10,000,000 shares authorized, none issued</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $0.16 2&#47;3 par&#59; 300,000,000 shares authorized&#59; 198,690,593 issued at March 31, 2024</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital in excess of par value</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,369</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,346&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28,173</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,540&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,086)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(999)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock, at cost, 78,189,958 shares at March 31, 2024</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14,359)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,658)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,130</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,262&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total equity</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,186</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,318&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and equity</font></td><td style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50,091</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,065&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt-to-total capitalization ratio</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.8&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-4</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_124"></div><hr style="page-break-after:always"><div style="min-height:31.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows (Unaudited) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Dollars in millions</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.729%"><tr><td style="width:1.0%"></td><td style="width:67.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.365%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;three months ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</font></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">739</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,238&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on investment securities, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in net losses</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">226</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of property and equipment</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effect of businesses acquired and disposed&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivables</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,890)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,433)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">97</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(907)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits payable</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,488</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">754&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(422)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(238)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unearned revenues</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,934&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by operating activities</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">423</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,687&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions, net of cash and cash equivalents acquired</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(177)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(223)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investment securities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,259)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,313)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities of investment securities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">645</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sales of investment securities</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">391</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in investing activities</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(414)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,292)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipts from contract deposits, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">499</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,997&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of senior notes, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,232</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,215&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of senior notes</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of commercial paper, net</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(644)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(177)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of term loan</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(500)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt issue costs</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in book overdraft</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(20)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock repurchases</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(717)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends paid</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(109)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(29)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,207</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in cash and cash equivalents</font></td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,216</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,674&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,694</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,061&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period </font></td><td style="border-bottom:3pt double #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,910</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,735&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-5</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_130"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Consolidating Statements of Income&#8212;For the three months ended March 31, 2024 (Unaudited)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In millions </font><font style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.625%"><tr><td style="width:1.0%"></td><td style="width:44.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insurance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CenterWell</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eliminations&#47;<br>Corporate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues&#8212;external customers Premiums&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,448&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,448&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicare</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,258&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,258&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,311&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,311&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Medicare Supplement</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total premiums</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,261&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,261&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Services revenue&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military and other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total services revenue</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues&#8212;external customers</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,536&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,323&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,032)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,699&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,818&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,906)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,611&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,251&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,124&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,483&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,805)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,801&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,536&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,962)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,375&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from operations</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit ratio</font></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</font></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Consolidating Statements of Income&#8212;For the three months ended March 31, 2023 (Unaudited)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In millions</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.625%"><tr><td style="width:1.0%"></td><td style="width:44.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insurance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CenterWell</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eliminations&#47;<br>Corporate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues&#8212;external customers Premiums&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,809&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,809&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicare</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,190&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,190&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total premiums</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,550&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,550&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Services revenue&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military and other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total services revenue</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues&#8212;external customers</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,792&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,549&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,762)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,903&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,505&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,666)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,742&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,993&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,858&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,418&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,126&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,565)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,979&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,576&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,175&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,728)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,023&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from operations</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit ratio</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.1&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating cost ratio</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-7</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_136"></div><hr style="page-break-after:always"><div style="min-height:31.5pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Membership Detail  (Unaudited)      </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">In thousands</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.104%"><tr><td style="width:1.0%"></td><td style="width:36.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.980%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#366092;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average 1Q24</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Membership&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Individual Medicare Advantage*</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,548.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,539.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,153.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,408.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Group Medicare Advantage</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">551.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">551.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">511.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Medicare Advantage</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,100.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,091.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,664.2&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,918.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,347.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,380.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,956.3&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,849.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Medicare</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,447.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,471.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,620.5&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,767.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare supplement</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">323.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">319.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294.0&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State-based contracts and other</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,261.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,272.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,371.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,228.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Military</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,955.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,970.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,930.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,960.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total excluding employer group commercial medical</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15,987.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,034.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,216.7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,263.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fully-insured commercial medical</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">109.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">121.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.6&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338.7&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASO commercial</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">77.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total employer group commercial medical</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">187.4</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">210.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">594.0&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Medical Membership</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,174.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,244.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,154.1&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,857.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Specialty Membership&#58;</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dental&#8212;fully-insured (B)</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,099.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,108.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,327.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dental&#8212;ASO</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">303.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">304.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Dental</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,402.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,413.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,637.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,512.0&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vision</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,884.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,895.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,061.6&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,971.4&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other supplemental benefits</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">366.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">368.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Specialty Membership</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,653.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,677.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,114.7&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,868.3&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Member Mix<br>March 31, 2024</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Member Mix<br>March 31, 2023</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Individual Medicare Advantage Membership</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HMO</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,848.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,778.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PPO&#47;PFFS</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,700.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,375.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Individual Medicare Advantage</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,548.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,153.0&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Individual Medicare Advantage Membership</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shared Risk (C)</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,051.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,749.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Path to Risk (D)</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,785.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,755.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Value-based</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,837.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,505.1&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,711.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,647.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Individual Medicare Advantage</font></td><td colspan="2" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,548.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,153.0&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Individual Medicare Advantage membership includes</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> 922,200 </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Dual Eligible Special Need Plans (D-SNP) members as of March 31, 2024, a net increase of 140,100, or 18 percent, from 782,100 as of March 31, 2023, and up 50,900, or </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6 percent</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, from 871,300 as of December 31, 2023.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-8</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_139"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Premiums and Services Revenue Detail (Unaudited) </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dollars in millions, except per member per month&#59; includes intersegment revenues</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;three&#160;months&#160;ended&#160;March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Per&#160;Member&#160;per&#160;Month&#160;(I)<br>For&#160;the&#160;three&#160;months&#160;ended&#160;March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollar</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percentage</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Insurance</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Individual Medicare Advantage</font></td><td style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22,448</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,809&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,639&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,351</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,293&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Group Medicare Advantage</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,989</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,765&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,202</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">821</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">115</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State-based contracts and other (E)</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,311</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,909&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">576</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fully-insured commercial medical (F)</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">256</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,018&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(762)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-74.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">565</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">550&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty benefits (G)</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">239</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-5.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare Supplement</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">197</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">206</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Military and other (H)</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">252</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial ASO</font></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-66.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </font></td><td colspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28,537</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,806&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,731&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CenterWell</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy solutions</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,828</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,857&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Primary care</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,170</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,020&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Home solutions</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">820</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">628&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,818</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,505&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-9</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_145"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">CenterWell Segment - Pharmacy Solutions (Unaudited)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.062%"><tr><td style="width:1.0%"></td><td style="width:20.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.503%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:24.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For&#160;the&#160;three&#160;months&#160;ended<br>March 31, 2024</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">For&#160;the&#160;three&#160;months&#160;ended<br>March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">For&#160;the&#160;three&#160;months&#160;ended<br>December 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Generic Dispense Rate</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Medicare</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">91.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91.4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">91.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Mail-Order Penetration</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Medicare</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">29.0</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">CenterWell Segment - Primary Care (J) (Unaudited) </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.041%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">As of March 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">As of March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Year-over-Year Growth</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Primary</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Primary</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Primary</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Center</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patients</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Center</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patients</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Center</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patients</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Count</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Providers</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Served (K)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Count</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Providers</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Served (K)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Count</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Providers</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Served</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">De novo</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">113&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">162</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26,600&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">94.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69.8&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">95.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Wholly-owned</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">625</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">203,100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">191</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">586</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">180,700&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Independent Physician Associations</font></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">62,900&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58,400&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">299</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">900&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">318,000&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">249</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">748&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">265,700&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.1&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.3&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.7&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.020%"><tr><td style="width:1.0%"></td><td style="width:17.412%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">As of December 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sequential Growth</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Primary</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Primary</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Center</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patients</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Center</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patients</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Count</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Providers</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Served (K)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Count</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Providers</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Served</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">De novo</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">274</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43,100&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Wholly-owned</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">188</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">617</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">189,600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Independent Physician Associations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">296</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">891&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">294,200&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%">CenterWell Segment - Home Solutions (Unaudited) </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.145%"><tr><td style="width:1.0%"></td><td style="width:29.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.902%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">For the three months ended<br>March 31, 2024</font></td><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">For the three months ended<br>March 31, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Year-over-Year Growth</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Episodic Admissions (L)</font></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">84,260&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">73,937&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">14.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Total Admissions - Same Store (M)</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">102,236&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">96,358&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">6.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div style="margin-bottom:1pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-12</font></div></div></div><div id="ie9f95947fa4b47bb9d4fac3545599c9f_157"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Footnotes to Statistical Schedules and Supplementary Information</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1Q24 Earnings Release</font></div><div><font><br></font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.87pt">Net losses associated with the company's non-consolidated minority interest investments.</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.25pt">Fully-insured dental membership as reported does not include Humana members that have a Medicare Advantage plan that includes an embedded dental benefit. </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">C.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.37pt">In certain circumstances, the company contracts with providers to accept financial risk for a defined set of Medicare Advantage membership. For these Downside Risk arrangements, the provider is measured against a medical expense ratio target and the company may share savings from reduction to the total cost of care of the defined membership. The result is a high level of engagement on the part of the provider. Under these arrangements, the company may contract with providers to accept partial, full, or global financial risk. In certain instances (capitated shared risk) of these arrangements, the company may choose to prepay these providers a monthly fixed-fee per member to coordinate substantially all of the medical care for their Medicare Advantage members assigned or attributed to their provider panel, including some health benefit administrative functions and claims processing.</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">D.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:8.47pt">A Path to Risk provider is one who has a high level of engagement and has contracted with the company to participate in an Upside Only&#47;Shared Savings total cost of care arrangement and&#47;or in one of Humana&#8217;s Quality Bonus programs (Model Practice), through which the company rewards the provider for achieving quality and utilization targets. Providers who are contracted in an Upside Only&#47;Shared Savings arrangement may receive a portion of achieved surpluses when the actual cost of the medical services provided to patients assigned or attributed to their panel is less than the agreed upon medical expense targets. These contracts may also include a Downside Risk trigger (future date or membership threshold) which has not yet been met.</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.86pt">Per Member per Month (PMPM) shown reflects only Medicaid premiums and average Medicaid membership for the period&#59; includes impact of dual eligible demonstration members. </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.18pt">Fully-insured commercial medical premiums also include stop-loss premiums associated with the commercial ASO product&#59; for purposes of the PMPM metric, the commercial ASO stop-loss premiums have been excluded.</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.3pt">Specialty per member per month is computed based on reported specialty premiums and average fully-insured specialty membership for the period.  </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:8.38pt">The amounts primarily reflect services revenues under the TRICARE East Region contract that generally are contracted on a per-member basis. </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.46pt">Computed based on average membership for the period (i.e. monthly ending membership during the period divided by the number of months in the period).</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">J.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.73pt">De novo </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">refers to all new centers opened or acquired since 2020 under a WCAS joint venture</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">.  Wholly-owned </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">refers to all centers outside a WCAS joint venture. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">K.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.52pt">Represents Medicare Advantage (MA) risk, MA path to risk, MA value-based, Direct Contracting Entity, and Accountable Care Organization patients. </font><font style="background-color:#ffffff;color:#ee2724;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">L.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.61pt">Reflects patient admissions under the Patient Driven Groupings Model (PDGM) payment model.</font></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">M.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.83pt">Reflects all patient admissions regardless of reimbursement model. Same store is defined as care centers that have been owned and operated at least the last twelve months and startups that are an expansion of a same store care center.</font></div><div style="padding-left:9pt"><font><br></font></div><div style="padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S-13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>a1q2024humanaincpreparedre.htm
<DESCRIPTION>EX-99.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2e6044c2f12c4e24b51196a0f0a7aac3_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2024 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;24&#47;2024</font></div></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:72px;margin-bottom:5pt;vertical-align:text-bottom;width:238px"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%">Please view these remarks in conjunction with our 1Q 2024 earnings release that can be found on our website at </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%;text-decoration:underline">www.humana.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%"> under the Investors section, or via the following link&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;humana.gcs-web.com&#47;financial-information&#47;quarterly-results.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%">We also invite you to listen to our live question and answer webcast with our Chief Executive Officer, Bruce Broussard, our Chief Financial Officer, Susan Diamond, and our President and Chief Operating Officer, Jim Rechtin which will begin today at 9&#58;00 a.m. Eastern Time and will be available at via the following link&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;humana.gcs-web.com&#47;events-and-presentations&#47;upcoming-events</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%">. For those unable to listen to the live event, the archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page via the following link&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;humana.gcs-web.com&#47;events-and-presentations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:700;line-height:120%;text-decoration:underline">Cautionary Statement</font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%">Certain of the matters discussed in these prepared remarks are forward-looking and are subject to a number of risks, uncertainties and assumptions.  Actual results could differ materially.</font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%">Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission, and our 1Q 2024 earnings press release as they relate to forward-looking statements along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements in future filings or communications regarding our business or results. </font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%">Today&#8217;s press release, our historical financial news releases and our filings with the SEC are all also available on our Investor Relations site.  </font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%">These remarks include financial measures that are not in accordance with generally accepted accounting principles, or GAAP. </font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%">Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today&#8217;s press release which can be found via the following link&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;humana.gcs-web.com&#47;financial-information&#47;quarterly-results</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12.5pt;font-weight:400;line-height:120%">Finally, any references to earnings per share or EPS made during this conference call refer to diluted earnings per common share. </font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify;text-indent:21.6pt"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2024 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;24&#47;2024</font></div></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Management Commentary</font></div><div style="margin-bottom:3pt;padding-right:-4.3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:167%">Key Messages&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">First quarter financial results exceeded internal expectations and consensus estimates, driven primarily by lower than planned administrative expenses, some of which is considered timing in nature </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The first quarter benefit ratio is in line with expectations as we have taken a more conservative approach to quarter end reserving considering the Change Healthcare disruption, although certain key individual Medicare Advantage (MA) early indicators are largely in line to slightly positive to expectations</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">We raised our full year 2024 individual MA membership growth guidance by 50,000 to 150,000, supported by higher than anticipated non-DSNP sales </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Based on results to date, we reaffirmed our 2024 Adjusted EPS outlook of &#8216;approximately $16&#8217; and full year Insurance segment benefit ratio guidance of approximately 90 percent </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">We are proud of our continued organic success expanding our Medicaid platform with recent contract wins in Florida, Texas, and Virginia </font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:-4.3pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Looking ahead to 2025, we expect benefit levels, plan stability and choice for seniors to be negatively impacted as a result of the final MA rate notice, which is not sufficient to address the current medical cost trend environment </font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.33pt">Considering the significant difference between the final rate notice and our previous funding assumption, combined with the inherent pricing limitations imposed by the Total Beneficiary Cost (TBC) change thresholds, we no longer believe $6 to $10 of Adjusted EPS growth is the appropriate target range for 2025</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.33pt">We remain committed to margin recovery and profitable growth through multiyear pricing actions, creating value for our shareholders over the long term &#8211; though now believe the recovery process will be longer than previously anticipated</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.33pt">Our 2025 Adjusted EPS growth outlook will be impacted by several variables into which we will not have clear visibility until later this year.  As a result, we believe it is prudent to provide more specific guidance for 2025 once we have greater clarity  </font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.33pt">We are evaluating plan level pricing decisions and the expected impact to net membership along with opportunities to drive growth and further productivity across all lines of business to support 2025 Adjusted EPS growth</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.33pt">Importantly, we believe in the strong fundamentals and growth outlook of MA and expect that the industry will adjust to the current funding and regulatory environment, continue to deliver strong top line growth, and normalize at an appropriate margin of at least 3 percent over time</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">We continue to believe there is strong bipartisan support for the MA program and that the strong core fundamentals and growth outlook for MA and value-based care (VBC) remain intact.  Further, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2024 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;24&#47;2024</font></div></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">we expect that Humana&#8217;s platform, unique focus on MA, and expanding CenterWell capabilities will allow us to compete effectively and deliver compelling shareholder value over the long-term</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">First Quarter 2024 Results and Full Year 2024 Outlook</font></div><div style="margin-bottom:7.2pt;padding-right:-4.3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;Today, Humana reported financial results for the first quarter of 2024, reflecting a solid start to the year.  Adjusted earnings per share for the first quarter were $7.23, which was above our initial expectations.  This outperformance was primarily driven by lower than planned administrative expenses, some of which is considered timing in nature.  The first quarter benefit ratio is in line with expectations as we have taken a more conservative approach to quarter end reserving considering the Change Healthcare disruption, although certain key individual MA early indicators are largely in line to slightly positive to expectations, as discussed more below.  </font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Based on results to date, we have reaffirmed our 2024 Adjusted EPS outlook of &#8216;approximately $16&#8217; and full year Insurance segment benefit ratio guidance of approximately 90 percent.</font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Further discussion of our first quarter performance and full year 2024 outlook are in the sections that follow.</font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:174%">Individual Medicare Advantage </font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Individual MA membership growth to date is positive to previous expectations driven primarily by higher non-DSNP sales.  We now anticipate full year individual MA net membership growth of approximately 150,000 as compared to our previous expectation of approximately 100,000 net growth.  From an industry perspective, we anticipate overall individual MA growth of approximately 6 to 7 percent, with the impact of Medicaid redeterminations and related implications on DSNP MA membership which is projected to have a one-time negative 100 basis point impact to industry growth in 2024.</font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Revenue for the quarter was slightly favorable to expectations driven by the higher than anticipated membership growth, along with slightly higher than anticipated member risk scores.  We continue to expect our premium PMPM yield to be in the lower mid-single digits for the full year.  </font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Now turning to medical cost trend. We experienced modest favorability in prior year development in the quarter primarily related to the third quarter of 2023 across both inpatient and non-inpatient categories.    With respect to current year utilization, inpatient admissions per thousand </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2024 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;24&#47;2024</font></div></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">(APT) were in line with expectations for the quarter.  APTs ran slightly higher than anticipated in January and February, offset by favorability in March. As previously shared, we have limited visibility into non-inpatient trends and inpatient unit cost until claims are received, and so as is customary, our first quarter results assume these costs items are in line with previous expectations.   </font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">While we have seen some positive early medical cost indicators in both prior year development and current year utilization, we recognize the Change Healthcare disruption is impacting claim submissions and therefore took a more conservative approach to quarter end reserving resulting in a benefit expense ratio consistent with expectations.</font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">All-in, acknowledging it remains early in the year, we are cautiously optimistic about the performance of our individual Medicare Advantage business relative to our initial expectations.</font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:174%">Medicaid</font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Our Medicaid business performed in line with financial expectations in the first quarter. We were very pleased to receive a statewide award in Virginia as well as a regional award in Texas during the quarter.  Humana was the only non-incumbent to receive an award in both states, validating the strength of our Medicaid capabilities and value proposition for our state partners.  Further, we are incredibly proud of our recent statewide award in Florida, building upon  decades of strong performance in the state. </font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Looking ahead to the full year, the Oklahoma contract successfully went live on April 1st adding approximately 190,000 members, and we are actively preparing for the Indiana contract to go live this summer where we expect to add an additional 35,000 members, bringing our total active Medicaid footprint to 9 states.  At this time, we continue to expect an increase of 250,000 Medicaid members for the full year, growing to approximately 1.5 million members by year end.   </font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">We are excited about our momentum in Medicaid. We believe it validates our vision toward delivering unique value to communities by building on a strong operating model that integrates physical and behavioral health and develops meaningful partnerships and innovations to address health inequities and social determinants of health. We anticipate continued investments to grow our platform organically with a focus on procuring additional awards in priority states, with request for proposals (RFPs) currently active or upcoming across several new state programs.</font></div><div style="margin-bottom:7.2pt;text-align:justify;text-indent:22.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:174%">CenterWell</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2024 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;24&#47;2024</font></div></div><div style="margin-bottom:7.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Within our Primary Care Organization (PCO), we have seen strong patient growth year to date, adding 8,900 patients or greater than 20 percent growth in our de novo centers and 13,500 patients in our more mature wholly-owned centers, representing 7 percent growth year to date.  Aiding this growth is improved patient retention, which increased 80 basis points year over year.    We continue to anticipate our end of year patient panel for 2024 to be between 330,000 and 340,000, as a result of organic growth and programmatic M&#38;A, representing expected growth of approximately 35,000 to 45,000 patients year over year. </font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">As previously shared, we expect a margin headwind in the PCO in 2024 because of the initial phase in of the v28 risk model revision. While we expect a margin headwind in the near term, we continue to anticipate we will largely mitigate the ultimate impact of the risk model changes over the three-year phase in through a multi-pronged mitigation plan, including numerous operational efficiencies such as centralizing and streamlining administrative functions, standardizing the clinic operating model, investing in new clinical models to continue driving improved patient outcomes, and improving clinician productivity to increase capacity. These mitigation efforts continue to make the expected progress.</font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">As we continue efforts to drive integration of our CenterWell assets, we doubled the number of CenterWell primary care patients serviced by CenterWell Home Health under value-based care during the quarter, adding 20,000 patients as of March 31st.  In addition, we are pleased to report that the voluntary disenrollment rate for Humana health plan members who utilized two or more CenterWell assets in 2023 was 400 basis points less than members who did not utilize CenterWell in 2023.  This speaks to the opportunity we have to provide differentiated member experiences, centered around ease, convenience, and improved health outcomes, leading to increased satisfaction and loyalty.  </font></div><div style="padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Capital Deployment</font></div><div style="padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">We recognize the importance of returning capital to shareholders and have completed $715 million of share repurchases year to date, taking advantage of the dislocation in the stock price relative to our confidence in the long-term earnings outlook of our business.  This is underpinned by our strong Medicare Advantage platform, further expansion of our Medicaid footprint, and the continued build out and integration of our CenterWell assets.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2024 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;24&#47;2024</font></div></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> From an M&#38;A perspective, we remain focused on opportunities to enhance our CenterWell capabilities, with a particular focus on growing our Primary Care and Home businesses.</font></div><div style="padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Earnings Seasonality</font></div><div style="padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">We expect second quarter earnings to be approximately 37 percent of our full year 2024 earnings. In addition, we expect the second quarter Insurance segment benefit ratio to be slightly higher than our first quarter ratio given the seasonality of favorable prior year development.  Finally, we anticipate the Consolidated benefit ratio will be approximately 40 basis points less than the Insurance ratio.</font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">Looking Ahead to 2025</font></div><div style="margin-bottom:0.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">We expect benefit levels, plan stability and choice for seniors to be negatively impacted by the 2025 final MA rate notice, which is not sufficient to address the current medical cost trend environment.</font></div><div style="margin-bottom:0.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">We continue to assess the impacts of the final rate notice and Policy and Technical Rule, as well as the Inflation Reduction Act (IRA), and are finalizing our pricing decisions for the 2025 MA bids which will be submitted by the first Monday in June.  We are taking a granular approach to our bid strategy, assessing the needs and benefit preferences of various consumer segments, the current and expected profitability of our offerings and greatest opportunities for attractive membership growth.  We anticipate utilizing a combination of targeted plan and county exits and varying levels of benefit reductions, among other actions, to optimize our portfolio for both the near and longer term.  While we always strive to minimize benefit disruption for members, given the constraints of the current landscape, we anticipate significant impacts in the near term, which the industry must manage in partnership with CMS.</font></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Considering the significant difference between the final rate notice and our previous funding assumption, combined with the inherent pricing limitations imposed by the Total Beneficiary Cost (TBC) change thresholds, we no longer believe $6 to $10 of Adjusted EPS growth is the appropriate target range for 2025.   We remain committed to margin recovery and profitable growth through multiyear pricing actions, creating value for our shareholders over the long term &#8211; though now believe the recovery process will be longer than previously anticipated.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2024 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;24&#47;2024</font></div></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Our 2025 Adjusted EPS growth outlook will be impacted by several variables to which we will not have clear visibility until later this year.  As a result, we believe it is prudent to provide more specific guidance for 2025 once we have greater clarity.  These variables include finalization of our MA bid pricing decisions, the continued evolution of industry cost trends, and the level of competitor pricing actions in 2025 which will impact our net membership growth.  Finally, we continue to evaluate opportunities to drive growth and further productivity across all lines of business to support 2025 Adjusted EPS growth.  </font></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Importantly, we believe in the strong fundamentals and growth outlook of MA and expect that the industry will adjust to the current funding and regulatory environment, continue to deliver strong top line growth, and normalize at an appropriate margin of at least 3 percent over time.  </font></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">We appreciate the desire for more detail regarding our outlook for 2025 and will therefore provide an update on our bid strategy post bid finalization, with a further update in the Fall once we have visibility into competitor plans and expected membership implications.  As is customary, we will provide formal 2025 guidance on our fourth quarter earnings call early next year.</font></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">MA Industry Value Proposition and Growth Outlook </font></div><div style="margin-bottom:0.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">The MA program has strong bipartisan support and is increasingly being selected by seniors as they view it as the best option to receive affordable, high-quality coverage that meets their unique needs, with benefits such as a zero-dollar Part D premium, transportation benefit for rides to the doctor, and dental, vision and hearing coverage.  </font></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Today, more than half of all Medicare-eligible seniors and those with disabilities rely on MA &#8211; more than 32 million Americans</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. MA has a higher overall share of diverse populations at 29 percent, compared to original Medicare at 19 percent and MA plans represent a larger share of low-income enrollees versus Original Medicare</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. 38 percent of enrollees with MA coverage have annual incomes of less than $25,000 as compared to 23 percent Original Medicare enrollees</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. These statistics underscore that MA is deeply valued and relied on by millions of seniors, particularly those with lower incomes and that are underserved. </font></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">In addition, MA encourages utilization of VBC, resulting in more proactive and comprehensive care and better health outcomes for beneficiaries.  Data on Humana&#8217;s 2022 individual MA plan members show patients in VBC models were 3 to 11 percent more adherent with their preventive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humana Inc. First Quarter 2024 Prepared Management Remarks</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">04&#47;24&#47;2024</font></div></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">screenings and medications</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">, and experienced 7.1 percent fewer admissions and 12.7 percent fewer ER visits versus patients of non-VBC providers</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.  Further, Humana&#8217;s MA members in VBC arrangements experienced 30.1 percent fewer in-patient hospital admissions than individuals in original Medicare</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.  </font></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">As we look ahead, the Medicare population will continue to grow. And given the clear benefits of MA and VBC, Kaiser Family Foundation anticipates there will be 70 million Medicare eligible Americans by 2030</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">, with MA penetration rates greater than 60 percent</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.    </font></div><div style="margin-bottom:0.6pt;padding-right:-4.3pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:7.2pt;padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">Closing</font></div><div style="margin-bottom:7.2pt;padding-right:-9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Humana had a solid start to 2024.  And while we acknowledge that the entire MA industry is navigating a difficult near-term environment, we continue to believe the strong fundamentals and growth outlook of MA and VBC remain intact and the strength and scale of our platform and differentiated capabilities will allow us to effectively manage through the uncertainty, compete effectively and deliver compelling shareholder returns over the long term. </font></div><div style="margin-bottom:7.2pt;padding-right:-13.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">We appreciate your continued support and look forward to providing updates on our performance and outlook throughout the year. </font></div><div style="margin-bottom:7.2pt;padding-right:-13.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:7.2pt;padding-right:-43.2pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Bruce Broussard, Chief Executive Officer</font></div><div style="margin-bottom:7.2pt;padding-right:-43.2pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Susan Diamond, Chief Financial Officer</font></div><div style="margin-bottom:7.2pt;padding-right:-43.2pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Jim Rechtin, President and Chief Operating Officer</font></div><div style="margin-bottom:7.2pt;padding-right:-43.2pt;text-align:justify"><font><br></font></div><div style="margin-bottom:7.2pt;padding-right:-43.2pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Centers for Medicare &#38; Medicaid Services, Monthly Contract and Enrollment Summary Report, December 2023. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Advantage Demographics Report - AHIP (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">www.ahip.org&#47;resources&#47;medicare-advantage-demographics&#63;utm_campaign&#61;Daily%20Dispatch&#38;utm_medium&#61;email&#38;_hsmi&#61;290599646&#38;_hsenc&#61;p2ANqtz-9USb2APbw2aE2NJDbXJjooMTEcgpKdT85E8CBDJC07NOQUrB_u3CknKqye_l6Beb5vSlUOor4M6uK4JKdS1e5742YvQg&#38;utm_content&#61;290599646&#38;utm_source&#61;hs_email)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Humana&#8217;s 2023 Value Based Care Report, https&#58;&#47;&#47;humana.gcs-web.com&#47;static-files&#47;2d174b46-2f41-4ab9-acc4-2f400b703c10</font></div><div style="padding-right:-43.2pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> U.S. Census Bureau, Projected Age Groups and Sex Composition of the Population&#58; Main Projections Series for the United States, 2017-2060. Available at&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;www.census.gov&#47;data&#47;tables&#47;2017&#47;demo&#47;popproj&#47;2017-summary-tables.html</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kaiser Family Foundation, Medicare Advantage in 2022&#58; Enrollment Update and Key Trends, August 25, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>hum-20240424.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:2b487e96-c580-4c35-9cbd-437df9e49a5a,g:341cf7a6-891e-4b2d-a62f-be78f1573eba-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:hum="http://www.humana.com/20240424" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humana.com/20240424">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hum-20240424_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hum-20240424_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.humana.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>hum-20240424_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:2b487e96-c580-4c35-9cbd-437df9e49a5a,g:341cf7a6-891e-4b2d-a62f-be78f1573eba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_88c963ec-d5e1-4d60-84e1-a77e308e422c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_85710b4e-761e-4af0-a2ae-471e0291b959_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_2d1fad70-6112-49d1-a55e-7d8bf97935b2_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ac9f3950-cac5-49fb-8bf0-71dd7d2da702_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7dd627a9-51ac-4b04-9ec5-4b8a42773ac9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a97dcb58-0468-412a-a6dc-4846a2a77f12_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d7162105-ff96-4b07-9d53-46ec9ff19fa5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b87a6643-492a-44a4-b9e8-0282b5206fb5_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_02509219-f089-4131-9879-b42f843d9e0d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_dd9536cc-6f59-414f-9c02-1b1675dee6b1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_de481cab-34df-4774-b14d-84fc1644fc6e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_3d777e6c-fe2d-4e55-b1d5-378c10dab101_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_d7a28afb-8423-4c3c-b672-bc6624b6fa39_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2f298e89-be6d-44cf-8794-bf533725289e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_38841213-4692-43c4-88c3-83e0d4bc0d9b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b03785fa-6c28-44e7-beeb-f9d7615fa3d9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f7c2a29f-2f82-4e69-a9f2-88421644e19f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_55b9f6f8-f120-4d52-9fa9-a4eca92c9fb1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_88bac1fb-248b-4498-9a60-2694b87b76f6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_648b4d5b-c353-4e42-a03c-84ad59ebdad5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_00cf3b18-1641-4bec-b920-4fd4e1ec1694_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_87ee6fcd-38e2-4232-aee1-731878f0146c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3b3f1601-bb30-4a63-b073-9fd2934fe1c8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>hum-20240424_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:2b487e96-c580-4c35-9cbd-437df9e49a5a,g:341cf7a6-891e-4b2d-a62f-be78f1573eba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humana.com/role/CoverPage" xlink:type="simple" xlink:href="hum-20240424.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0778cb07-1601-4f2b-99e0-5ef4a35ba354" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_DocumentType_0778cb07-1601-4f2b-99e0-5ef4a35ba354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3ede3fe6-aeda-4ddf-8f14-0ddd2cfcf0bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_DocumentPeriodEndDate_3ede3fe6-aeda-4ddf-8f14-0ddd2cfcf0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ebf96be3-3adf-46a3-a8b1-b48aae125e18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_EntityRegistrantName_ebf96be3-3adf-46a3-a8b1-b48aae125e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d8a36614-9a9f-4fe3-907c-cf4dc03a68ca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_EntityCentralIndexKey_d8a36614-9a9f-4fe3-907c-cf4dc03a68ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_67b976bf-6cdf-4c2a-a435-d9f506cf760a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_AmendmentFlag_67b976bf-6cdf-4c2a-a435-d9f506cf760a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b670295a-2660-46b9-9236-f18a501b8ee2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b670295a-2660-46b9-9236-f18a501b8ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_eac81589-0f0d-4079-9e94-ca5596d281c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_EntityFileNumber_eac81589-0f0d-4079-9e94-ca5596d281c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dc6fcbfc-14f2-4578-9393-e271472e4135" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_EntityTaxIdentificationNumber_dc6fcbfc-14f2-4578-9393-e271472e4135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_db070cd2-404c-44ab-84ed-99b63499a153" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_EntityAddressAddressLine1_db070cd2-404c-44ab-84ed-99b63499a153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3b609042-9c54-4a4a-a227-a2757f4fdac7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_EntityAddressCityOrTown_3b609042-9c54-4a4a-a227-a2757f4fdac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_15a30a1f-517a-4fd7-adc7-a1e06457fb10" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_EntityAddressStateOrProvince_15a30a1f-517a-4fd7-adc7-a1e06457fb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_60362982-aa1a-40df-ab27-9e91bea71b6d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_EntityAddressPostalZipCode_60362982-aa1a-40df-ab27-9e91bea71b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4a668dd3-a12c-403c-ac7b-0b7860be4c4b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_CityAreaCode_4a668dd3-a12c-403c-ac7b-0b7860be4c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_579a72ff-646a-4cc3-a4a9-b189216a162a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_LocalPhoneNumber_579a72ff-646a-4cc3-a4a9-b189216a162a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7ad72223-877f-4a6a-9b2c-b254d070596c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_WrittenCommunications_7ad72223-877f-4a6a-9b2c-b254d070596c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_07035571-1a2d-454e-abd3-1a724faeae6d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_SolicitingMaterial_07035571-1a2d-454e-abd3-1a724faeae6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_4a332603-2ce0-47cc-b254-f86271b538ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_PreCommencementTenderOffer_4a332603-2ce0-47cc-b254-f86271b538ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_83cb621f-570c-4706-ae94-62080a598828" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_83cb621f-570c-4706-ae94-62080a598828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_736a424b-db04-47a8-a26b-56f19508198f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_Security12bTitle_736a424b-db04-47a8-a26b-56f19508198f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8f8a3ece-35fa-4e39-ae06-6cc9fbdf1382" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_TradingSymbol_8f8a3ece-35fa-4e39-ae06-6cc9fbdf1382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1e6d921a-0368-44e4-97bd-8fca0ea75347" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_SecurityExchangeName_1e6d921a-0368-44e4-97bd-8fca0ea75347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e2505ff7-4847-4b99-ab5f-d5cc3b4892fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b4636585-144d-42a4-93bb-d216888388ba" xlink:to="loc_dei_EntityEmergingGrowthCompany_e2505ff7-4847-4b99-ab5f-d5cc3b4892fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>humanalogoa05.jpg
<TEXT>
begin 644 humanalogoa05.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "D B$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS3$XZI.->5TB<OQ-2O)\[NCJJ***^\/;"BDI: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBBD 4444 %%%%, HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ^8_VW/\ D$^%_P#KXF_]!6ODVOK+]MS_ )!/A?\ Z^)O_05KY-K\
M5XE_Y&,_E^1\?F/^\,]B_91_Y+)8?]>TW_H-?=0[U\*_LH_\EDL,\?Z-/_Z#
M7W57V_"O^X_,]K+/X'S'444E?9GK%75/^0?<?]<V_D:_+Z;_ (^9/]X_SK]0
M=4_Y!]Q_US;^1K\OIO\ CYD_WC_.OS7C#_EU\_T/GLV^R-;I7Z3?#'_DGOAW
M_KRB_P#017YLMTK])OAC_P D]\/?]>47_H(K#A#^+4]",J^*1TV>.M)]*\Y_
M: \2:CX2^%^JZGI4YM;V)H0DJ@$@&10>#[$U\AK^T5X^[Z[)_P!\#_"OK,QS
MRAEM54JD6V>IB,;##R4)(_0(9SZFBOCWX%?'3Q?X@^)&EZ5J>H_;;*[+(R2*
M 1A2001]*^PQ7?EV84\QINK3T2-L/7CB(N41>HI...]'3 KB_B]XGN_!OPWU
MS6;$+]KMH08BPR 2P7./;.?PKOK5(T:<JDMD;RDH)R?0[3<.N:,U^?K?M%>/
MFR?[=D_[X '\JZSX3_''QGK_ ,1M TZ^UB2>TN+D))&5 R""<=/:ODZ7$^%J
MU(TU%ZZ'EQS*E*2BD?:V*2CTS7F?QH^-5K\(+73FFL9;ZYO_ #/)5" H*;<E
MB>WSBOJ:]>GAZ;JU7:*/4G.-.+E+8]-YI&8#^(5\2^(_VN?&&K,ZV$=MI<1'
MR[%W,/Q/7\JX/4OC-XTU1BT_B&\&3SY;[1^0KY*MQ5A(-JG%R/)GF=*.D5<_
M1(W$2]9%!^M/616Z,,5^:C^/O$<C%FUN])/)/GMU_.M'3_B[XQTR17@\07H(
M.0K2%A^1ZUR1XNHM^]!V,_[5AUB?HYD45\;>!/VO-<TBXCB\16Z:G:<!I8@%
MD'OZ'Z<5U'CS]LB"-3!X5LFF8J,W5V"J@D= O4_CBO:AQ%@)4G4<K-=.IUQQ
M]"4>:Y]0;@O4@#ZTSSXMV!(N?J*_/;7OCOXW\02,T^N3P(22$M_W8^G%8"_$
M#Q*DAD&N7P?));SVZGK7D5.+:"=HP;1RRS6FMHW/TJ##UI<]Z_/KP[^T#XW\
M-R(T>LRW4:D$QW6'!'ISS7TI\&_VEM-^($\>E:NBZ7K+#$?/[N;_ '2>_L?7
MBO5P/$.$QDE3^&7F=5''TJS2V9[I12;@>0>*6OJ3TAGIBES45Q,EO&TLCA$4
M99F. />OG+XH?M<66CW$VG>%H%U"="5:\DR(@1P=O][Z]*\[&8^A@8<]>5CG
MK5H45>;/I(MCDD"F>='G!=<_6OSWUWX]^.-?D9I=<GMT)X2W(0 >G'-8#?$/
MQ,T@D.NWQ<8^;SSVKY*IQ;0B[0@VCRY9K33LHGZ4!E[,*=GZ5^<%K\6/%]FP
M,7B&^&#G#2DC\C73:3^TSX\TMESJBW:+_#/&#_+FM*?%F%E\<&AQS2D]U8^^
M?>D_G7R/X?\ VS]2@VIK&C17"\9DMG*GWP#_ (U]9VEP+JWBF P)%# ?45]+
M@<RP^/3=!WL>E1Q%.O?D=R7-%<?\4?B):_##PK+K=W;27<:R+$(XB,EF.!UK
MYKU[]LK7KPLNF:5:V2<X:8EV_I@UEC<WPN ER5I:D5L52H.TV?8IXZFF-(J\
MEP/J:^ =4_:*\=ZKN#:T\"'^&% N/QZUS5U\3?%=YGSM?OW![&8@8SG%?.SX
MMP\7:$&S@EFM-;1/TB6XC;@2*3]13]V[H<BOS4C^('B2-PR:Y?*PZ'SF_P :
MZ#0OCUXWT&1&AUR>=5(REP0X(].:F'%M!M*<&D*.:TV]8GZ&4@-?-_PK_:TL
M]<NX-,\3P)I]Q(0JWD>?*)/0,#]W/KTKZ-AD6:-71@R,,@@]J^MP>/P^.AST
M)7/4I5H5ES09-112$@<FO2.@3I2=.X%>3?%K]H70_ACNLT_XF>LD<6L3#"<<
M%SV_G7S-XI_:<\;>))'$5ZNF0'($=JN#CW)YS7S6.S["8*7(WS2\CSZV-I47
M9N[/O S(O)<#\12K(C=&!_&OS9F^)'BF[R9=?OG.<\S$<T^'XF^*[?:8_$%^
MI48'[X]/3FO"_P!;J-_X;L<7]JP_E/TEX]12U^>^F_M">.]+VB/7)90#]V8!
MACGU_P ]*[G0OVQ?$]@RKJ-A::@@X)7*,?4\9KNH\48*HUSWB;PS*C+?0^SN
M3]*.V:XOX3_$2/XG>$H=:BM7L]\CQM&Q!Y4X)R*[3O7UM&K"M!5(/1GIPDIQ
M4H[#J***W+"BBB@ HHHH **** "BBB@ HHHH ^8_VW/^03X7_P"OB;_T%:^3
M:^LOVW/^03X7_P"OB;_T%:^3:_%>)?\ D8S^7Y'Q^8_[PST;]G[Q;8^"_BCI
MNH:C((K1E:!I"<!=X(!/L#C-??=IJ%O?0)+;SQS1.,JR,""/J*_+[T-:%OXB
MU6SA6*WU.\@B7@1QW#*H'H #BM<HSYY;3=*4;Q9>$QWU>+@U='Z<^<G]]?SH
M\Y/[X_.OS,_X2O7/^@QJ'_@5)_C1_P )7KG_ $&-0_\  J3_ !KZ#_6^'_/L
M[_[6A_*?I5J4R"PN1O'^K;^1K\P9O^/F3_>/\ZTV\5ZVP(;6-0.<];J0]>H/
M-97J2<GKSUKYC.LWCFCARQMRGF8S%K%6LK6!NE?I-\,?^2>^'O\ KRB_]!%?
MFRW2OTF^&/\ R3WP]_UY1?\ H(KV^$/XM3T.W*OBD<9^U-_R1?6O]^#_ -')
M7P6O?Z5]Z?M3_P#)%]:_WX/_ $<E?!:]_I7)Q9_OD?0QS3^,CTG]G3_DL7A\
M_P#31O\ T!J_00?=K\_/V=?^2Q>'_P#KHW_H#5^@?\-?1\)_[I+U/1RO^$_4
M4]J\S_:._P"2+^)O^N*?^C%KTP]J\S_:._Y(OXF_ZXI_Z,6OJ,?_ +I5]'^1
MZ=;^%+T9^?U=U\#_ /DK7A?_ *_%_D:X6NZ^!_\ R5KPO_U^+_(U^&8+_>J?
M^)'Q5'^+$_1$?=%?+/[<'W_!WTO/_:-?4P^Z*^6?VX/]9X-^EY_[1K]?X@_Y
M%M3Y?FCZO'_[M+^NI\M5>TG0]0UZY^SZ;93WL^!\D"%B >F<=/QJC7TG^Q0H
M;Q!XG! /^CP_^A/7Y)EN$6-Q,:#=DSY7#4E6JJ#TN>1CX)^.FA\T>&;\IV'E
MX/(SG'I7*ZMH>HZ#=&VU&RFLIQ_!-&5/X9ZCZ5^GNT>@_*O//C9\/K#QQX$U
M.*>",WEO"TUO-M&Y&4$@ ^^,?C7V^*X5ITZ3G1GJM3V:N5QC&\'JC\^..,C%
M&T4IRI((P1UXI\"AIHU(R"P'X$U^<*+<N4^?MK8T="\(ZUXFD$>E:9=7S9_Y
M8QE@#Z9Z5L:I\)?&6BVK7-YX=OX85 )?RB0/R[U]_P#@K1;#1?#>G6]A:Q6T
M/D1DK&H R5&3]?>MUHU92&4$8]*_2J/"=*5).=35H^BAE<7%.4M3\ML$,01@
M]P>#4EO<2V<\<\#M%+&P974X((.00?4$5[-^U7X%M/"/Q AO+"%;>UU6'SC&
M@PHD4X; Z '*GCN37BO/;K7P&+P\\%B)4F]8]3PJM-T*CAV/T(^!/CT_$3X=
MV%_,VZ]AS;W/^^O&?Q!!_&O1.Q]:^7OV)=2D:S\46))\N*2"8#W<.#_Z *^F
M[B98+>61CA54L2?:OVK*<2\1@85IO6WY'V&%J.I1C-GS!^UC\79[.9?!^E7#
M1$H'OI(SS@\B//;(Y/U KY8X/)'-;/C+Q!)XK\5:MJ\S%FO+EY1GLI/RC\!@
M?A6+SD #/I7Y!FF,J8[%2G)Z7LD?*8FLZU1NY8LK&YU*X2"TMY+F9C@1Q*6;
M\AS^-=9'\&?',R!T\,:BRL,C$7:OKK]GOX3V/@7P;97LUNCZU?1K-/,Z@LFX
M9" ]@ <'U.:]=VCC 'Y5];@>%8U:,:E>5FSU:.6*4%*H]S\X+[X4>,=.0O=>
M'-0BC4<DPD\8)SQ[ UR8]^:_4>YC5H9,@'Y3V]J_+C_&O#SS**>5\G)*_,<6
M-PL</;E=[BG')%?J!HW_ ""+,_\ 3)?Y5^7[=*_4#1?^039_]<E_E7N\'[U?
MD=N4_:/'_P!KS_DDDG_7Y#_,U\/\=.U?<'[7O_)(Y/\ K\A_F:^'Z\OBK_?E
MZ'-F?\=>A)!;37<RPV\4D\K=(XU+$_0#DUU%C\)_&.I1[[;PYJ$J'D'R2./Q
M^M=+^S2 WQFT($ C$AY_ZYM7WPJ+C[H_*C)<CIYE1=6I*UF/!X*.(ASR9^=-
M]\&?&VFQ-+/X;OA$HRS+'D <^GTKCKBWEM9GBGC:*53AD=2"/P-?J05'IQ]*
M^:?VOOAS9'P[;^*K2W2&]@F6&Y:-0!(C$@$XZD-CGWKLS/AF.&P\JU&5^7H:
MXC+E3@YP>Q\E],D=>V*^R?V2_B7-XF\.W/A^_F,MYIH!B9CEFA/0?@>/Q%?&
MU>N?LLZP^E_&'380Q"7L4MNP['"E@?P*_K7A9%BY87&P2>DM#BP-5TZL4GHS
M[OKS7X]?$Q?AGX(FN8&!U*Z/D6JG^\>K8] .?RKTL?KBOBG]K_Q,^J?$B'25
MDS!IELH*9X\R3YB<>ZE/RK]0SO&/!8.4XNS>A])C*WL:+DMSQ"^OKC5+R:[N
MY6GN)F+O(Y)+$GDDFH-I8@*"3V Y-!SVKZ._9+^%5GX@FN_%&JVZW,-K)Y%I
M%( 5+@99B.^,@#/O7Y!@<)4S'$JE%ZO=GR=&E+$5%%'C6E_"GQAK-L)[+P[?
MSQ-T98B!^M69O@WXXMU+R>&-05?7RB:_1:.%8U 50 .@ I^P-QMK] 7"-"RO
M-W/>65PMK(_+S4=-N])O'M+VWDMKF/&Z*12K#/()!JO7K/[4JA?C1K( POEP
M?^BEKR:OSC&4%A\1.BG\+/GZU-4ZC@GL?</[(O\ R2*WS_S]3_\ H=>U_P 5
M>*?LB_\ )([?_KZF_P#0J]K_ (J_;\H_W*EZ(^RPO\&/H.HHHKV#J"BBB@ H
MHHH **** "BBB@ HHHH ^8_VW/\ D$^%_P#KXF_]!6ODVOK+]MS_ )!/A?\
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M!(PQ^)J.V_X^(O\ >']*DO\ _C_NO^NK_P#H1J.V_P"/B+_>']*_GO\ Y?\
MS_4^"7QGZ;^'?^0#I_\ U[Q_^@BM'_"L[P[_ ,@'3_\ KWC_ /016C_A7]!T
M?X<?1'WD/A1\H?MN?\A+PF?^F=S_ #CKYBKZ<_;<_P"0GX2_ZYW7\XJ^8Z_%
MN(/^1A4_KH?'YA_O$CZ@_8A_X_/%_P#NVG\YJ^C/'TSV_@?7Y4.UTL)V4^A$
M;$?K7SG^Q#_Q^>+_ /<M/YS5]%?$4_\ % ^(?^P?<?\ HMJ_0<D_Y%"]&>_@
M_P#=4?FKTX[U>T&W6ZU[3H'&4EN(T;Z%@#^AJCW-:?AC_D9M)_Z^X?\ T,5^
M2T]:Z3[_ *GRL?C7J?IE8QB&TAC7HJJ!^ JQZU%;\0I]*E]:_H2GI!(^\CLB
M&Y_U$GT-?ENO45^I%S_J)/H:_+=>HK\YXP_Y<_/]#P,V^Q_785NE?J!HO_()
ML_\ KDO\J_+]NE?J!HO_ "";/_KDO\J7!^]7Y"RG[7R/'_VO?^21R?\ 7Y#_
M #-?#]?<'[7O_)(Y/^OR'^9KX?KR^*O]^7^$YLS_ (Z]#U+]F?\ Y+-H7_;7
M_P!%M7WV.E? G[,__)9M"_[:_P#HMJ^^UZ5]1PG_ +G+U_R/4RS^"PKRK]IR
M%9O@OKZL.%$+#ZB9"/Y5ZK7EW[3'_)%_$7^Y'_Z-2OI<RUP=6_9G=B/X4O0^
M Z]"_9_)'QB\+E3@_:#^1C8&O/:]"_9__P"2Q>%_^OEO_0&K\0R__>Z?JCXS
M#_Q8^I^A7\/O7Y[?M!SO<_&7Q.[\L+A$]>%C51^@%?H1_#G/&*_/+X]_\EB\
M4?\ 7U_[(M?H_%E_JD/4^CS3^$D<"W2OO+]EZQ2S^#VD;0 9FDE;ZES_ $%?
M!I[U]^?LT_\ )'= _P!QO_0C7SW"D4\9)]D>?E?\5GJ5)2TE?KA]2?!?[4W_
M "6C6O\ KG!_Z*6O)J]9_:F_Y+1K7_7.#_T4M>35^!9K_OU7U9\/BOX\O4^X
M?V1?^21V_P#U]3?^A5[7_%7BG[(O_)([?_KZF_\ 0J]K_BK]ERC_ '*EZ(^N
MPO\ !CZ#J***]@Z@HHHH **** "BBB@ HHHH **** /F/]MS_D$^%_\ KXF_
M]!6ODVOK+]MS_D$^%_\ KXF_] 6ODVOQ7B1?\*,_E^1\?F/^\,]B_91_Y+)8
M?]>TW_H-?=0KX5_91_Y+)8?]>T__ *#7W57VW"O^X_,]K+/X'S'4445]H>L5
M-4_Y!]Q_US;^1K\OIO\ CYD_WC_.OU!U3_D'W'_7-OY&OR^F_P"/F3_>/\Z_
M->,/^77S_0^>S;[(UNE?I-\,?^2>^'O^O*+_ -!%?FRW2OTF^&/_ "3WP]_U
MY1?^@BL.$/XM3T(RKXI'%_M3?\D7UK_?@_\ 1R5\&#O7Z"_M$:2^L?!WQ-#&
MN7CMQ/\ A&RR']%-?GTO05S<61:Q<7T:,\T3]JF>E?LZL%^,7A[)Q^]8#/\
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M7XKQ!_R,:G]=#X_,/]XD?4'[$/\ Q^>+_P#=M/YS5]%_$*,R^!O$"(,LVGW
M ]_+:OG3]B'_ (^_&&?[MI_.:OJ6]MUN[6:&0;DD0HR^H(((K]$R*//E48KL
MSZ#!*^%2/R[]N]7_  _,EOX@TR5SA$NHF8^P8$FD\0:3+X?US4=,G!$MG</
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MY!%>E&I&;M%W.I23V):***V&%%%% !1110 4444 %%%% 'S'^VW_ ,@?PO\
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M_7 _X5YG$V'JU,:I0BVK'/F4)2K*RN=5^S/_ ,EFT/\ [:?^BVK[Z["OBO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>humanalogoa051.jpg
<TEXT>
begin 644 humanalogoa051.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "D B$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS3$XZI.->5TB<OQ-2O)\[NCJJ***^\/;"BDI: "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@ HHHH ^8_VW/\ D$^%_P#KXF_]!6ODVOK+]MS_ )!/A?\
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M!(PQ^)J.V_X^(O\ >']*DO\ _C_NO^NK_P#H1J.V_P"/B+_>']*_GO\ Y?\
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MN7CMQ/\ A&RR']%-?GTO05S<61:Q<7T:,\T3]JF>E?LZL%^,7A[)Q^]8#/\
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M7XKQ!_R,:G]=#X_,/]XD?4'[$/\ Q^>+_P#=M/YS5]%_$*,R^!O$"(,LVGW
M ]_+:OG3]B'_ (^_&&?[MI_.:OJ6]MUN[6:&0;DD0HR^H(((K]$R*//E48KL
MSZ#!*^%2/R[]N]7_  _,EOX@TR5SA$NHF8^P8$FD\0:3+X?US4=,G!$MG</
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MY!%>E&I&;M%W.I23V):***V&%%%% !1110 4444 %%%% 'S'^VW_ ,@?PO\
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M_7 _X5YG$V'JU,:I0BVK'/F4)2K*RN=5^S/_ ,EFT/\ [:?^BVK[Z["OBO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" %U!-4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML#[E-7!#D4Z@# HIK5#"BBBF V0 CFF!0.E2,,C%-*%14M1OJ)J^IQ7QY/\
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M>/0TKJ]ABT44A< XHN@%HI-XI00>AI@%%)NP<&@L!WH"XM%-#^HI2P'>DFF
MM%-9^.,T!L#DTP'44A<=J9YV/>DW8:5R2BF[SZ4X'(S36JN*^M@HHHH ***0
MD 9-#=D M%)O6@.#2335P%HI-ZTH(/2DIQ86"BBDW*>]5<!:*,@]#12YD 44
MA.!D4F\^@I[@.HINY_[OZ4I8 XH%="T4TN.PI00>E2Y)#%HI"P7K06P,BG=7
M 6BF[SZ"@.<]*8FTAU%(S;3C%"ODXQ0',KV%HI"X% <&CI<+J]A:*,CUHR#T
M-)23&%%%(S@<4P%HIOF'T%.H ***,@=32<D@"BDW+ZT;ESC-.X"T4A< XHW
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MJ>K/R_-_]ZEZB4J]1]:2E7J/K7R<CS:>S'0_\?*?]=!_.OU\_8#_ .2$6/\
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M^,^];2;2YKE:VN/('8TH( Y;-1">$C(E7\Z#-'CB0?G252.S:%>ZO<>3DT$
M]13!-'T,JY^M.$B'HP_.KYJ<ENM"5==1R$ \TI*'FF9YP*>$!&<TN9-\I=K"
M,5SA:5.E-*;3G%.0=Z?(ANP[ -(.#@]S2TW>I/!Z4G9JY+?01B0V107)IK2#
M<>*:9HU/+#\Z4G&4;MA)J!*B]\TZH1<Q 8$B_G2BZC_YZ+^=1*M!*[873'LA
M'(%( 0<D5&]W"?XQ^=*+A'&%8$?6M(U*;2LP4DW8>2,Y6DYS2KC^*E)VCH,T
ME&7.QM\H!< EJ4MC@\TPG)YH9A]YC5*U["5V.)V< 4F]O6A6&.F?2C>H^\!4
MW]W4K8-SDX%&QO3]:1IHD^8MBH)=6LHC\]T@^K4O:4H+5HASBNI8VD=C2* .
MKU0G\4Z1"?WFHPCZN*HS_$#PQ"<2:M"#Z>:!7/+&X9O621#K4X]3?+''#_I3
M?,P<;JYW_A97A1>3K,'_ ']%6+;QUX<N@)(M5@()X_>"I_M#"[*2$J]-]3:)
M)/-(,]S5.'Q%I4XS'>Q'Z,*L1WD$_,,JGZ&MXXJA/9HT4X3T3)E8C@TE("#Q
MFG8XSD5LFI:C7NB49(Z&C('6@D ]?SI.HEHB_=844QYD3J:K3ZU86_\ KKN-
M?7<P%8RQ5.'Q,SE.)>7;C!I&0 <M6-<^./#EH,SZM /K**KCXF>%68)_;%N0
M>A\T5G_:&$O\2(]K23W-\,.@YI<GTK+A\6^'[E08-4@R?^F@JY#J5G-Q'=(V
M?1ZTAB:51:215Z<W=2+'XT@0#K0'1ER"*3:QZM^M;*:MW*<G'1#J>HPHJ-B<
M9!_*GQDE15+FZCY4M1U%%%, I'SMXI:;*2$XI.S6HF[*XWZ4GS<<?6A22,D4
MFYL\BA12V8E%S5QP!/04N&7FC?QQUI%D8]Z3<8A=IV%R1\N:2D:1,Y)&>]03
M:G90?ZRX1?JPJ95815VPYXHL;MO.:5?W@R&_"LR7Q5H<'$VHPY]Y!563XA^%
MX'VG5H ?3S17++,,)#>2)=6GW-PMSM'/M2A6Z@5BP>.O#<PW)JL!_P"VHXJS
M#XLT:;E-2A(]G%0L?AY[2!3I=)&H>F3Q3?WE5$UW3)>%O(_P<5-'?0R?=D4_
MC73#$49;2*4H/9CRK#VI5.#FCSD(X--W+ZUI^[DQN0YFW=J3);FCM2@XY%#J
M4WHBK*PE'2@\\XI'SCBK2;=Q)*3%SGO2-N XI8B,X].M(S@\C!IR:V&[1=[
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ML<&GT@ W9!I:I;!>X4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?>GQ?ZK\*_F26[1^;R]UJPUA@@COUK7\!*&\6VF>TZX_,5D.0,9]:V/ ./\
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M'05)MS^%)*0BAS^(J.;W_0Q;;1TOPG^)&M?#3Q);Z_H]\\(24%]AZ@&OU?\
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M#::M VQH9@PQ[5^PG[&OCU_''P=TB_EFWN+1=Q)SW-?C2SJ6* X)'!K],/\
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MM3?^6E2/U_"OPQ12U/BV]!M?3_\ P2G_ .2ZW_\ UXI_Z$:^8*^G_P#@E/\
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M +![?S%?C!XF_P"1AO?^OAJ_"O%/_>:?H?'\2_&O0HT445^-=SXN.["ON/\
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M7\*C_P"6E22<M^%?AWV3XKHAM?3_ /P2G_Y+K?\ _7BG_H1KY@KZ?_X)3_\
M)=;_ /Z\4_\ 0C7U/"/_ "/*7J>MDW^]P/U.@_U0J9/NBH8/]4*F3[HK^KZ/
M\-'Z6OA&2_<;ZU^:_P#P5J_Y'RW_ .NB_P#H)K]*)?N-]:_-?_@K5_R/EO\
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M(_"C]"MJ%%%%4,*CNO\ 4M_NFI*CNO\ 4M_NFLJW\)B>Q^2G_!23_DXO6/\
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M1>@^E*WWC7\O5?XC/S66LV(/O_\  :LZ'_R$8?\ >JL/O_\  :LZ)_R$H?\
M>KIP'^]Q]2Z'\0_83]BG_DCVG_\ 7!/_ $&O9!]TUXW^Q3_R1[3_ /K@G_H-
M>R#[IK^M,A_Y%E/T/U7 _P"Z1] _@_&A/O"C^#\:$^\*]CJCJ^P*.I^AKYG_
M ."G?_)M>M?]<?ZFOI@=3]#7S1_P4\ '[-FM#_IB/YU\]Q7_ ,B>IZ'GYBKX
M.?H?E"/N?\"I],'W/^!4^OY.Q?\ $9^6OXPH Q10?ND@\UG33<D$-9'ZB_\
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M#]X4OM".+^.QV_"[6R?^@;-_Z :_%/QB0?$UV1_STK]K/CUS\+]:'_4.F_\
M037XI^,1CQ-=@?\ /2OPWQ0?[V"/B>*-)Q,RBBBOQA[GR3W"OM'_ ()&_P#(
MSZE_U]+_ .@"OBZOM'_@D;_R,^I?]?2_^@"OLN!_^1Q ]C)/^1A$_1^) 8P<
MT\G:*9#GR@0:<2VS-?U'3:5-,_2T?.O_  4:;'P0NC_TSE_]!%?DJO4_6OUG
M_P""C.3\#+L^D<O\A7Y+8?.]3P#S7X!XCKFQI\)Q+_'3) 0>1128#<K]WZTI
MX4CVK\H>JT/F)KE:8UV &*_3?_@EFN[X=OS_ ,M%_P#037YC''2OTX_X)8$C
MX=R$GCS!_P"@FOT?PXDI9NHGT7#^N-3/KT]?PIXY&:CY/-25_24-C]!"BBBK
M *CNO]2W^Z:DJ*Z/[IA_LFLJ_P#"8GL?DK_P4D_Y.+UC_K\:OGQO]4/]ZOH+
M_@I)_P G%:T?2[;'Y5\^,?W:BOY.XJUS>IZL_+\T=L7+U$HHHKY=:3/,>Z/0
M?V6/^2WZ1_UU/\Q7[-^"O^1:L?\ KVC_ /017XQ_LLG'QNTC_KJ?YBOV<\$\
M^&K+_KVC_P#017[WX9_[M+U/N>&/X4F:Z]_K3*>O?ZTROV'HCZLD7H/I10.@
MI&W#I3NKV#<6BFY?W_*E4L>M%P%HI&SCB@9(YH3N M%%%, HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "F7'^J;Z&GTRX_U3?0UG5_AL3V/RC_X
M*>_\EUO/^OIJ^:V[?2OI3_@I[_R76\_Z^FKYK;M]*_E#B[_D;U/5GY?F_P#O
M4O42E7J/K24J]1]:^3D>;3V8Z'_CY3_KH/YU^OG[ ?\ R0>Q_P!]OY"OR$B
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M_K3(O^193]#]5P/^Z1] _@_&A/O"C^#\:$^\*]CJCJ^P*.I^AKYI_P""GO\
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MHDXK5BCL/ZT4T2*>,')[4K/M .T\TDXRV&+13?,]J<#D9JDK %%%%, HHHH
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M\HV7[C?6OS7_ ."M7_(^6_\ UT7_ -!-?I/+]QJ_-?\ X*UD#QY;DG_EHO\
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M &@/VO/ /PLT:9TUN"2Y52!"LGS9KR\PS+#8:A*4YI:=S&KB*-.+YI'Y]?\
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M!-?!>(&F4RU/'SSF>"9\<@X I:11\HI:_F1M-L_.9I\]V)@9S5[PS_R'K?\
MZZ"J)SO'TJ_X9YUZW_ZZ5W9<N;%12[FE*WM$?LQ^RKG_ (4]HI/_ #X1_P J
M].[9->9?LJ\?![1L_P#/C'_*O2F)S@FOZUR&#674_1'ZI@_]VCZ"'DYJ0'/(
MIJA2.:$[UZ[NM#H0K D?C3=O!SVI],8G)IPLEJ#>J.*^/7_),-:_[!TO_H)K
M\5O&7_(SW?\ UTK]J?CSS\,-:X_YATO_ * :_%;QD/\ BIKL_P#32OPWQ0Y7
M5B?%\2NU5,S****_%GON?(*5VPK[0_X)&G_BI]1!'_+TO_H KXOK[._X)'Y_
MX2?4O^OI?_017VO!/-_:T#VLDDOKL3](8ON#Z4M%NN8U)]*5C\W(K^HJ#Y:2
M9^D]2.7 SA>3P:^.?^"G7P"/CCPN/&6F6F;BQBV%E'."23_*OLE@H)(].*YK
MXE>#+3QKX8N="O(05GC/7UP?\:\;B#*XYO@)4F<.8T/;T&C\-+B*2TF>UD3!
M1RI!'H:C!8-G'7I7MG[8G[.>L?"#QY</%:LMI-)^Z(3C)R37BD9E+E'3&.M?
MROFN JX3%RI35M3\XQ6%^K5FF/8E%R/RI) 0%DZ<<XIR*"X#'H:;P92.H]J\
MJ4'#2,CS9JK.>A:TC7M4T&_2^TN\>-U.00V*]W^%7_!0#XJ^"$CM+S4'GBB
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MV2?A3W\.VWU\E:]6VC^^*0@#HU8+(,N<K^S0+!89?9/.M"_9I^&GA^\6^L=
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M'^&$"NV;<!UH3H:[Z.1Y=0^&"-E@\.E;E,K3_!VAV"@6^G1*/9!6C#86L/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "DVC.<TM%)M@(R[J%7 Y I:*2;
M,#T%-921\H%.HJ@$5<4%03FEHH **** "BBB@ HHHH ****  \C%(J!>]+10
M $ C!H P,444M "C'.?2BBC0!&7)S1MY! I:*8!1110 4444 -=23D4FQJ?1
M4N:0#0A'IFEVY'('X4M(Q('%*[EL FQ1W-(,9]J 23@DTX*!R!1R6W8-"D>E
M,P1D[N_K3Z0JI[4<@#23TS2ITQ04(Z<TJ @<BJ2L-M6%HHHIB"BBB@ HHHH
M#GMBDQG[P%+10 8'I1@>@HHH 0J#VH  Z4M%3<!&!/0TM%%";8!1115 %!&>
M]%% "; >I- 0 YI:*FX!1111< HHHJ@"BBB@ HP#U%%%)L P/048'H***5P#
M ]!1@=Q1133N 4  <CO113 ****FVH!1115 %%%% "%@#@TA 8?**5MF>:
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M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140158770868512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Apr. 24, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 24,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Humana Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000049071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-5975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">61-0647538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 West Main Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Louisville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">KY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">40202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">580-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ S#286 =!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " #,-)A8_2Z95>X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " #,-)A8F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,PT
MF%@TES!^*@0  %D0   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " #,-)A8GZ ;\+$"  #B#   #0
M        @ %M#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,PTF%B7BKL<
MP    !,"   +              "  4D/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( ,PTF%@9117U-P$  "<"   /              "  3(0  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #,-)A8)!Z;HJT   #X 0  &@
M    @ &6$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #,-)A899!YDAD!  #/ P  $P              @ %[$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  #%$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="hum-20240424.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="hum-20240424.htm">hum-20240424.htm</File>
    <File>hum-20240424.xsd</File>
    <File>hum-20240424_lab.xml</File>
    <File>hum-20240424_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "hum-20240424.htm": {
   "nsprefix": "hum",
   "nsuri": "http://www.humana.com/20240424",
   "dts": {
    "inline": {
     "local": [
      "hum-20240424.htm"
     ]
    },
    "schema": {
     "local": [
      "hum-20240424.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "hum-20240424_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hum-20240424_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.humana.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20240424.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20240424.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.humana.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0000049071-24-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000049071-24-000021-xbrl.zip
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M^J!=$6? #V@I@[UA!)6-.Z.U3IHJQ]A=DH*20=EE+6:,C.@2,XH4\A9&E4W
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M]460NN7Z%%2P'N&6.#L#)%ZNDRX2%S\*P+38)F@%,*T IA\<8'I0^L=5'QC
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M'E6IJ\+[(O.T':01(H1'V+-UW_:W CL%O'9-BHJF8Z$G%$:Y"J1+@PM2'R1
MRU2QH;IJV>HZRMV17,III_I(1;SIIDO"G&" 4$0C4G=1U3V@#4ITK!#)<'Q
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M@^.>7-]<Z_]G\N?831+-'S@@2V:$O_+FT(^A_D2K>/9 S\KU FE78[?%*.C
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MO]ZBVW[X_(RM;\O/^&V8!C/X#W+VR_\'4$L#!!0    ( ,PTF%@Z9G;M!!
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M^#P+R,#N\5D1WGT[/%02^TXT&O$$ZR((BA+)6.*OAV?WLD=.1G$036"-YZ6
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M':7MA7T=]UOF#]=L=W^VBDZPV^_EZ#=02P,$%     @ S#286(\V+.,@"@
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MVR7: +=>JS-[HQ[+LAXS U9DSR..O!CK,;2[#NL;Z(O9QVR^^6,/0C@34'.
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MII 7O;RJ=;:(5=52)/G^>:=>;]]LUY]<?'2>Q-W,T:+6L*IU7'S";;5_PW[
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M10IV@8[-);L'=1:'#UW>H,L;EXR'H.1P4@!D> ^%O4*P>%Q_LISLV32XL-\
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M#1C'*@#Y: ?&:./HP&[M9.5!0TAGP1WYVP3<\4!CVE83EX>"S3//79J.C./
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MA*E:R9MLDJK/=A!2"3[\*7VR0-1O<_T[J!<Q4D8Z#Y\*_"_1B[@:\:^T\C@
M%T*[U;!38#P)+-J?5>AY6,B+Y,9IP2[0-Q9[7V[=(;"=ZR!0T_)!XA1')#$K
MF'<%UA81ZV$L"Q1\#P0J I6+LZ^05HYI:0%=G/.0U/\IY-U70(Z<&Z57(!'(
M0SF#F?:G!'^:\Z3(_FM:F8Y.6Y"@QIY+^($!](D,18(\PK'8Q\1YS<3F^XE2
M5+$3[5<)Q)#0#N0X00C![2&3D1CI/"I<@:H&OJ''YBDD\):"@!RXJ"2 %H<+
M]FAEER/V!;]D;W1L2$$R0OA]@GSS@+,0S%5T3XQ")&I(6"2^)>H=(1^O2LF6
MTFIGD9%RRTYW5[%'#\/$/5@VZ2,P@,%&0S.=;.F-@A1S0DY(.Y?:PF37LYU[
M-.5H@:J[WK[9K@W_8/X0C=SY_%_#JI+A/5=VOUC;6U2#SZ[V7'RC?!#V65+,
M+#OE>QY@Z+_',9B@P_<XJ'+M)3498BNA_7<LE2:%WT'URFC>;LO8K2B$*%04
M'-;6)IH?9%$^9*KAP[(V8ZXA9A$*8  B00$PAB;* "XR/"K[\LS7T!LS&[;?
MIXQ_XFRP61TX? A(AN4U.KY;P3[/"E'OK0>WJS@H_'5+5LL?:)^&8J"JS67N
M 1D60R=']7+"QOF3),TKD%RI%Z#)/L<O&'('TYT4%ZDG_:AE+;)FW.U +:;-
MCG7=JF[28MIH6_5Z<1OIIBVFC:K5JI=K,5UGV'K7ZK;:Q]ZY6N;4UMTWSNZ]
MU[)D3\._Z_-OKS6-JFL1;[U&PBT?Z+,^*7:A>O2A28G6T-B]E6[4$R!'T=&Q
M1]:->T2L\EU[ YG9SPE91T2E9<.K/$>=,;$*Q*U6ZIC 8RE?/2(V6Z3<ZG+5
MHG#F1I& N:#/208']C"G-:(&)?J$]Q_AP(K7W-[D-%VRW*&\LD&97>UX%84)
MO)"B'#'U6P<J3Z6\9PPO]+D,B.AI9BV_,SN3,'H1LH^!!/=RRFYQP _!@'N)
M2TR%-6(@;4JR>R((AW*L\F1P:>Q1LF*I.O1%<?9IL_#&YA$%5?CY\?-1!4A6
M5'^<+4@=!(N^@"\0<CNMB41)'BA.I /O#Q6MI!#5@W,;DUC"8YD2LT3*L@%+
MD/E_ 2<$JKSZ5PR(@1C5J_5:6EF*J5&5CV8.-H]BFC2@:J1?*$?+V06&)*G,
M4X]U"2.%8VDG@]4M1G*+GN9CI#$3W],E5[,K_9Q7$13G;TY%3O*5T;')R:VJ
MB\=V&50@6 ,L(JU',&@=]UQIN],KX%E,)P$WH5X,9^7UA]2& RX]A?.N'U)1
M I9R9)2B7@Y>@8TN_@C4F8T%)*H>(JUCV4B=;5LNYJX*](MQV 4&KF4?S71W
MFK%#=!!\15WTT0O*6N58.Q*=!P^$*Q:=MX<P9K=Q>L>!9/8CE>3H](L.*60R
M]YD6@%D+4B"H?!BD4F>T23IG+=GX5T()^GT#:F"ZV?. Q6W54*3;);#92/2"
M&,UCE'%0A@TM]/LS8C4\Y$+#PL<]X8F^U.JS\K"&K;"ED&EFZ.7O%L9?OB#_
M(?,9O>3:@@S>Z6+922G]XN-%#JK.[2$/!I2LS=J\,U7L>P.?RES2^5+3E2H,
MFO6T*N,EZ;:B*!'8TU2V2G6MBCU#?@]C51(\H-Q_EA**<^_G*:7R]GA>LA^'
MV:" NGIFMNN" "HR ,LD(LB2P2BI$ A!T)1$Z$5;!PF-'&2SM=G47(&+"DB3
MXDKC7IPLTJQ]GLK! $B&F6E@P[&J1]<-6O/+F+<_YNO2<8F)JO2#M+)DP;_@
M $\4H -4H9/7L7!ON6AO5@8W+RLY=LA<_7R!'8)'J4NU(A"/^3%3\5O5B):I
MG6R4*IK=U_Z]G:L0UZ'1N:,-M*'F>RO82XCZ=;VYB[#/(7B:VOF9B@;5G\RJ
M22AE88DL>ON+G)%4'@/CY!T$4E2HJOHC=(F9L](%R"]BW4"J\F]Y2$4UM_GF
MF-F;D+?63K7T%N"'3ZE)/M$YT<XX)[^Y][*[Z[K5:-<V*;MK5ZU.MUPAVUIO
M=KBV:HWF]H?M6.WKXJ]W6W:WGY>[[:QD*^%U,'1N/[S__.&WMZ]??;E[C=)^
M ? !3W*I"70W-7%'_(+U0Y<+'D.5Q4D7"FY9 G?AJ*3OJCA <>#Q'!GW7;U;
M:==J1U8@> CZ%)0DU=N5ZV9.6=*1OD5X_V\$>&S6T)R:6BR=5)=4WW$(9P='
MB._H4-8GRQWY6W11.Y8#=7=PT/063W@_RM.E#_?NA2=R OQ%_;I;7C[FB7)@
M_#J['2K"KTJUL_$>G<*AX/.H>S:OKM_X)/"-O/5#$/%X8 P=M$:C5$?)CBAW
MGFY=J])NK=-MLG'8^>$ _I,[ *AE#@!:<0#0Z20X6M6-SA5H5ZUZM;Z+!$>U
MV]W%&[$;)8<U"8[B!,?;]Y__\^G5^]L[]OGNEW=W[[^8+(?)<I@LA\ER[,>(
M[E3:W:[)<JPPA[O5XWD/N8G8G7<\>QL1.Y-Q./Z(G7F-WY$BW&XC=H<@XO'
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MTIYG>+4<DI@SS;9G8C4:K>.'Y1T?:;:K_K<SYZ@BP_1Z740_X.%B!VR?._,
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M:(*U46G/&#1?GSGRX==*KI^3GM6AD?@!4^8MEI Z4BGZB!05'GS00R^0S(L
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MD%:SK]"3M_'-L8-I*5?=@S-4RVFXR1.YZX.88D!(0+PL^PW(G@F"9W\E;KQ
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MS[<N(OP$[)P@=.,%$C +6117:LW=ZBAK-4H&)7[8 $JN,[+;)'%Z8APJ"><
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M]>(%@6H\VSI\+!4$ME3U%_* 1C6>5:-8C\B&C$XCAG K$Z!U^%B,%]C02YD
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M\+PB.Z18I\DFY\*9SO%E]PQEI1N,HZ)YM=44?,MHK(*?51U]SF>9GUE5*-H
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MX.8SZ/<A[/<-*%A>,,=$&W*U=D/NFV5DY[QC"'I#O3LP#QE#8 UTHVL>?5Z
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M($ORCS:JG3YE"1=9A](/<")W+-0(UM[__$%;]L\K]BM=:H)]OP$-Q+=]$/G
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MSM; Z)!/7J@@3?O1L2Q(8ZD@35,DCPK2J"#-L:R6;@.DD K2*$Q^W$+:-\M
M!6E4D$:]2KWJ?*^ZN+E_1F<=%O(-_C--/#WIJQ0?F:/Q^W*RU0U.MGJD6+$,
M.U2,6\6X58S[2*K\[P7#YE0YHHIRJRAW$YU.*LHM<*PCH[^H67:XBG*7G;)A
MZ*:*<M?*P)_V\'JOE#F K_KT-9MAE?3I ZM*GCY]THFK]J-%27/ CFXUHS6@
MDFT-N5+-'-K IG_QH6Q.R+@OE+B^&[O<C:X&"1U-8)UZD)#\ JMU:%%F7O.F
M$4^*GRO!I037\8TRE=MV!$6[[1E!I;Y*4SY?Y5..JBEL]'0F8]LQN<0OVMF[
M <$>8%."6^6VJ>0,E9RADC-4'P*5H:$R-!IJ.JD,#5$'H=H0U&B^M :YBD_9
M?JS&1ED4*HE!)3'(2M0JB4$E,>R3Q-!520S2"0#Y(CRJSX'<L:#+J@XOLXJ:
M$ I2;0X4(C]J@754EP-IQ;9TD:"&5#<_,H/UO0\V'B.3,)B1U',?^-&I(* "
M;2K0I@)M1Y+T>=(-EJ2K0FTJU*9";8VU3'>&VDZW?WGLE^=#>W@4 !R/]N31
MM9\;FF4.:B>^BPN4O)X%L(C_B7H8&D6!XU)T'SVX\92XJ'NZ$Y<KG:X?4__.
MA1_+ R,U0%(>^CY,XE8&2QNIOB\?P;>]!*Z^R&CKRJ)*E,C&^8P/\=+MQ.?+
M1HN2R.CPX!K*8WM8]SL[%:)4Y6JUA2AE Z(\8N:YW:GBJS@5V-JHC8(-:O;,
M"PWZ&,/' Q[7AG74H(_QV+$8Z)2_&KT@9]:I^'M_83X+J><M-/(P93Z)IXQ,
MW#"*R9@N4'&F9 8/F9()7!01M)_) V-?F3\F04BFB/T4;T93&F]FWQPVYX8V
MW/S_43^AX8(8Y K;)O^;T?"'B+RABQ<:7ESMT+HE8:KS$0YOV PF ^#]@H3,
M8=A,@[A@*W#8> OR@1L1(0,K@LW<9$;F=#$#;!+N_9L/MP@Y!(]' ;29A9'!
M&+^ &^_=($D?J9/?$=)K[L0F &E$(S?"LW4CXE ?@!4E7DQ<GSC ^RC\_1<@
M!% SP,RA$:"5%SQ$6T$0UW>\!#<'T "@ J)Y"*YX2A&*(6-+P*=PCG1R S>R
MOQ+X)8?,L(S <9*0KXF1U1G.@Q".;RFE=ZPE#N#RB<? GA2OSEZ)NV+4F69;
MPBMG-'8$'?#>Y?!D]FW.8&&1?I1SW"? K9N]+<Z:?EC4YOJ\4=>>J=M&_Z"H
M:T?O#>S:XIA[A5R'>J=?_O7!D5Q\;+6X<R.BKLL6]><*@7UD<4KQ.5H'9D.=
MV+UW8Y=M9U <?8&E*2 EEC4P&WB!ARSIQ?KJSFP;JE"S"C4?&FH^."Q\5,9S
MRI&A3PH+GX1<V^L<Z%9*9+A0,[^O]8>#O8AO_ZC=3CA)1IC%8/KBSE#P@PU6
M9KB=E6POJKBJF*K3AGL-B"^=NM[OLK&C1 T&MM:UFU%\UY+"KC+CIX[0R9&7
M43T-GR^,2&9WU8$J\@B*JNK?B<#62J71&FYKC-6"./MZ&Q]W9JX[%0TS]_25
MI_3,[NTKYP4A7Z:,W/!]_,D\CT3LCBN,2[;E%B?V"Y\VBPCU">77\MOB 'X;
M$T13,F:@A6)N(L]3],>$YA,74T\RWH$.YO2]/T0\2E#VU@@^AVL39[KQ7G30
M![-9X'L+DL2N!U 8DTD0DGOJ)>*%\R2<!Q&L&(,[KHA?3!GUXBD/=8R9YP+6
M+N#58WAJN-!W1; 8,P=F][A\P"S@RGM@D-P>\GY/-ZSA(1[RWE"WAL/CNYUM
MW>A5+B#:[[$#59<DE8>\M#CIYNW'+V\___GVM]^VJI.:[2I7;FWEUE855/6K
M]:J"RAQ62<^Z5 O%ZM1.>G763YW?1?ZFBE&BVH65$W1/PK:CRIDM 3/K/FUT
M00W>;"FXK70><DF<XZICU+Z:EF7U&L":3]S[[%1%;FW'J3(%=; O5Z^Q#5F-
M17*E885]_/Z[(PCIP5C8=FL>1"YOGL7SLMU[EGI9Q:GE[TI?W%G=0D< TR0N
MOZ4LP%$!Z;ZX,Q81+([X',RH?W 1B2FFQ&^XNW)_3L-5W.:.78]"1K]>TPDL
M]B7U'N@B6M_2#(X@?7:O"R_?W'HI_!\IP+&J]!P[=@E.Q>#.^ 5Y]V]B=LPN
M%H/_ESDH9Y<"5Y0R1%C@@G$<42F3Q$G(B+LL-W=C-N-U"IA@[/M!3$:,,-CA
MC!<#T%C4),#O3"\/7.Q=LU2=)NJL$!&%3NP%^12Z04@^P0.",7G#[ID7S'E0
M*BN:2$-<!Q3M?_]=;_BJRN[KJGL8ZH->YY"HSK"G]RMF_>\5?C%UPZJUG*)^
MB^)1=_9.,7MDT^%D;NMW]#X(.;*?QN?_B)[R%!A*Y/Q_QXLC_RE*OFK*Z6Y/
M9.$X2M11!%.I4.)!T#G_=L%H&&$%:'#G\X0)UQ?Z0O4PH]0ALQ.:154"C4VE
M%0E\4'(0$C_K)Q"2M2\=U9^])Q.1G2$L?49_@#O^QS.7V1.[9W<'$]H==0>C
MD3WN3JAC];J]GFT[]N0_]N!9N1.!'^7PA,T<BE+2=O7KOJ$)?H0]$6YC,'60
M+IYD!IZO306WD;^@]>JS!Z1=C]&(K=(:)T'X0,/QM1<$7[&F)LKVA]?>P3?X
MX:_)C/HTGU X8]1/2W#P5V >]W ?N65.$O)27/(;_'4GHHV?&;QE1EX+8]NP
M[9Y._L1*_R02/,3U[\':!@8S!W,=WBWREC3^ZW+-\'ON\1C2?/O-F5+_CI$;
M,#'=*,)W7=V^O7E!)BX X0[NP,O@!7"F7GYK,SIF9+3 %@7+%AAT#F;I/5P'
M:P0TQ[_$OGEMR^ 5^A#@_>B%@N\FKL.R_@0/P($B?-9\&N)"B>=^901O,SNO
M,-0*IJ[&?S5>91^/F.<"D]WZG/K D-PYK'3K*Q=8EC_>^AA?YBU@'YZ7>CLV
MK\@\&5NWIOZ2*/N8YY&&;IHV!@#@&:AB>PC)R 6DI"&&C_%D^%684RI6)CP
M:6/.A;BW'+UT\C1/RIE)J%&+_3(%,MI%VGAHZ.:Z X,(,(XQ?MJI7VS.0J17
MBBG(/',@Q%3DT7]Y+XV A&[T%1 _\=/>($B.@M!H%"6S>4J[RV8@&J8>(*L
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M*U,R"WQTI8AW;RAE'&'@PD2@8,R)(>-^FE!'KP4_0\808C V7?="&%9W8?
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MUO*N>AME):]%>#6[(UU7:64EGS$PW-$&W0-+*I65+&^2?3";N:+5C9CA!'?
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MS[G-OU5H<R!/>X(R0*OF!&6!G%-"K'4D/]0K=\9J#<DW/?%HO=ZUNI!J077
M\#$)=:(2 26?_(;6.MB6WCEEL8/"C/J$_FDD>X.0V^CH)^T-4+.,_GM,0=N
MO\?N_4\_PA_96M(;K3X\>1Y$+F;>O@R9!Y+PGKUZ<,?Q-'UJ_BZQK9>=U2UT
M% 5>$I??DH.4PW#*R-& 8CP&%!/7<GO=7X*% R'_YS1<'?,=NQZ%C'Z]IA-8
MY4OJ/=!%M+Z7F>MG#^]UX>V;>Q8[^^G'$4)^^YWY)]'P#AZ6PE,0U'&@TJT$
ME5^3&?4I>>\[^OI*E[LXUTIN I]G^0AU[#:F,<-^]!$))D3DAZ>-E-X%(8FG
M#/X/&2,S>/ T(LP?LS'Y0$-G2BQ#(V;'M,C5'SY-QF[,QB].MKDE1?(GO71C
MN-RIL-WW/H'G>_]_>]?^W#ANI/\5U.QESY.B&+X?=C)5SGAF9^[.&6>\FZW\
ME()(R.(M12I\V.O[ZP\ *5FR18F2*!$ L:G,J(8OH/M#]X=&H[&6Y[[>M@WP
MV7&M$517FP8?M0BO)B=8#C&<Y^AR\>-JX5NBA/:!/G2U_@&RT? UDR??JR[7
M@\/55,>PR?BHIPOUA^NAH]*A\\KD5M<L2W7=YLN:JC=>V_9:75<]US_HM=NO
MV:;;]LE3>/W!"T!04>W56,]H]=J6T_<]2.$&CE<9'":"T5^3O,Q@$C0?;\(,
M^^=#H!]I4WY%<<R^1$63_:<XPCRTVBKWXP^6>T4XP<<TFZ<9YD[=ZH,/B;Q0
M2!0*%:;\7A\U43-@W#R4)3 &09EC*:,L!W<9FD7E3!:?YK(;3'?X+)6C^S[H
MI>E8-#RKBL(2#[5;%.*F9 A<AX\P*>##&PM[]-H ^WN.6G6-S9B8[BO>CEH]
M/11%ZB(>V]4T2 *72>"V.MQRH,B5&)<89PGC$F4LHZQO"B ,+?X)2VC>@A$+
MFCFC*ZZSH^ 3![;J3/DM(BA<%/?$2#1#@H-I<(BEGIZ-M3 ^?^GM\P)B2<$8
M#VYP=W,W$)_OZ,P=1,Z6^1=+W<(9=>GQ)3@&XO%[-=4'^'O#[OUXFVVU^A>.
M_QA'+TRM9T/1_>U[(%BKR,V6RQ@05H[R$A(L$E825H-2+-.^19@P!MU7,AK#
M')&.)$4&@R*G9_>EQ11EX"0LAR<8ZHI_Z!I9'Q6@V?)80P'):9S08& B 35@
M0 U%I<PZ$F&XS,=T-D-9$,$83,HX?AY%9'O3JZT/XL;Y=$73=QPXQ%,05L;=
M!Q=W9YY;2' PS1,X4D_/QEH8GW\_1\3A%\]@7!76;'5RL@  ,NSMY7FX&MO2
MG _.G$M?+\$Q$%_?JZD^Q5;_E=)*]?,C<O.E8:UD;D1)B)+B<N1W6,.K79[&
MNK#/J>EE4NA].9_'M%[7JWIG8B-==^6.8NEWI,HE. 0$!Y]E7'=89)GCN2G'
M<UY7#Y(YGH2]*K;-:AX.#PY@0%@95C(>\VQ!PHI'6 TE(>(DCJ6OU1&743YS
MC[+'*$ YR*J2B:WK(1XN^38E]!BUN</LM4CRZ:J%PBR0?DEG"-"C*-9*ZPLQ
MN6W#"UCT\*>E@QPIT-1/>L8,-\H37,V\CE,NA7V.,26,=[R;PFP&@V?I(=D:
M>=)T+B;)EB&5)[Z:>1VG7 K['&-*' ^913.8/8-C2YYPA _A5JYELL).DZ#I
M4MT2& .P!6*II]=Q*XR/OXWBJ"!.?EGW8R">7G>EV9?&7*I<@D- <(BEGEY-
MM3">?J5$QO7]MX%X>>GDI1V7*I?@$!$<8JF',Q_/^"Z6_%7NY^!K>>Y:^!&D
MHAYKNPUX@HAKNQ(B$DP,L V^ #44E?J^ #4\624L-4_)ZW&#&XFR!/][4.:X
MKR@[S7Y<GN!GV(KK2Q(C_8XD,9+$2!(C2<QA7L11;(M''M/O[D=Y)TMW2JC(
M.R54Y)UGA0I#$^G-KOUK@N?,.7H@I2>7\^G!3YMW;(D4A+[*6<X1NV85USJP
M'K\$B833:SA=8#PYQGNQH30493(< >&?KCRBO*!D)4J"=#:4+8;^@0%:%LV
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M, 0,S3ZT K$P@0 QR,7U_;>AT E3,\7?*2"<SBSQ=394*F%J_J';3261$ ,
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M3K:#-*==H=W ?Y,KBUZN]N5G_._8+)5Q0=H(P13K <3H$<7D*90\P*I#@'R
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M U!+ 0(4 Q0    ( ,PTF%@D+X;=%2$  -7$   >              "  0
M  !A,7$R,#(T:'5M86YA:6YC<')E<&%R961R92YH=&U02P$"% ,4    " #,
M-)A8.F9V[000  !G>   $               @ %1(0  :'5M+3(P,C0P-#(T
M+FAT;5!+ 0(4 Q0    ( ,PTF%AE\M_];@(  '0'   0              "
M 8,Q  !H=6TM,C R-# T,C0N>'-D4$L! A0#%     @ S#286(\V+.,@"@
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+ .,!  !*$ $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>hum-20240424_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hum-20240424.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-24</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0000049071</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-04-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Humana Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">1-5975</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">61-0647538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">500 West Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Louisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">KY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">40202</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">502</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">580-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">HUM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
